Đokić D I Saradnici. Epidemiološke Odlike, Faktori Rizika I Socijalnomedicinski Značaj Hroničnih Nezaraznih Oboljenja. Monografija. Kragujevac Institut Za Javno Zdravlje, 2011. 81-113

,
, 2011.
, 2011.

,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
( ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

19982008. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, O
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . .
5
5
6
10
10
12
15
19
35
38
39
40
40
41
44
45
45
49
49
51
57
62
63
77
77
77
81
81
86
90
94
98
99
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
,
. . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . . . .
, . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

? . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
100
101
104
105
106
109
109
110
115
115
120
122
124
132
146
148
151
153
154
155
159
159
160
175
176
178
182
183
185
185
187
189
190
194
195
196
196
,

. , . ,
. . . -, . ,
.
, . , . . ,
, , ,
,
. : , ,
. ,
. , , ,
, , .
: ,
, , ,
.
. , . , ,
, . .
() ()
,
[1]. (-10), :
(00-02),
(05-09),
(10-15),
(20-25),
(26-28),
(30-52),
(60-69),
, (70-79),
, (80-89),
(95-99).
, , . ,
. , , ,
. , , , . , , , [2, 3, 4].
.
, [5]. ,
[6].
[7]. , , . . ,
. [6, 8].
,
. [9].

20. . 21.
. .
.
,
[10, 11, 12].

[13]. , . 49% :
55% 43% [14, 15].
. .
(), 1990. 17 ,
2020. 25 [16, 17].
30% . , ,
, [8, 17].
, , 2006. 17,5 , 30% . 2006. 5,1 , 52%
[18].
. , , 41%, 32%, 27% [14].
, , , , 18 2000. ( 1).
, , ,
, , , , [19, 20].
.
: 33% , 39% , 48%
52% [14, 21].
, ,
, 1 2. 2006. 59 (27 32 ). 2006. (57,3%). 2006. 567,0
100.000 .
1. (DALY/1000) ; , 2000.

()

DALY/1000
18,1
12,4
8,8
6,7
5,7
5,3
2,3
1
2
4
5
6
7
DALY/1000
7,9
10,3
1,8
1,8
5,8
8,8
4,3
3,0
3
1
12
12
8
2
4
5
: The Burden of Disease and Injury in Serbia. Belgrade: Ministry of Health of the Republic of Serbia; 2003
DALY ,

1000
900
800
700
600
500
400
300
200
100
1998. 1999. 2000. 2001. 2002. 2003. 2004. 2005. 2006. 2007. 2008.
1. (00-99)
19982008.

750
706,1
700
672,1
658,2
650
668,7
657,2
657,4
646,4
626,1
645,9
610,5
600
627,3
624,3
605,9
612,3
606,9
598,9
613,1
577,5
574,5
550

500
1998.
1999.
2000.
2001.
2002.
547,7
542,7
2003.
2004.
2005.
2006.
2007.
528,1
2008.
2. (00-99) 19982008.
. .
2.
19982008.
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.

0099
99376
57336 (57,7%)
101444
58002 (57,2%)
104042
58098 (55,8%)
99008
54747 (55,3%)
102785
56754 (55,2%)
103946
57376 (55,2%)
104320
56868 (54,5%)
106771
60684 (56,8%)
102884
58925 (57,3%)
102805
57608 (56,0%)
102711
57343 (55,8%)
1130092
633741 (56,1%)

0099
3725
2156 (57,9%)
3961
2334 (58,9%)
3967
2161 (54,5%)
3800
2142 (56,4%)
4059
2275 (56,0%)
3999
2223 (55,6%)
3871
2203 (56,6%)
4320
2599 (60,2%)
4072
2474 (60,8%)
4159
2417 (58,1%)
4058
2406 (59,3%)
43991
25390 (57,7%)
3. , 1998
2008.
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
0099
2156
2334
2161
2142
2275
2223
2203
2599
2474
2417
2406
25390

1015
2025
86 (4,0%)
390 (18,1%)
37 (1,6%)
450 (19,3%)
56 (2,6%)
226 (10,5%)
23 (1,1%)
518 (24,2%)
62 (2,7%)
560 (24,6%)
65 (2,9%)
540 (24,3%)
76 (3,4%)
557 (25,3%)
99 (3,8%)
621 (23,9%)
36 (1,5%)
506 (20,5%)
41 (1,7%)
528 (21,8%)
55 (2,3%)
582 (24,2%)
636 (2,5%)
5478 (21,6%)
6069
512 (23,7%)
598 (25,6%)
608 (28,1%)
543 (25,4%)
583 (25,6%)
621 (27,9%)
575 (26,1%)
599 (23,0%)
536 (21,7%)
550 (22,8%)
570 (23,7%)
6295 (24,8%)
479,4 100.000 ,
( 2 3; 3).

, 2005. 632,6 100.000 ,
544,2 100.000 [12, 22]. , , , [20].
30
25
69
25
20
15
10
5
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
3. (%)
19982008.
,
. ,
, . , 100% , [19].
, . (American Heart Association), 2006. 430 , [23].

20. , 21. , . , 4 5 [24, 25, 26].
, .
10
. .
18,6
17,2
17,2
17,0
16,3
7,8
7,0
5,5
10
12
14
16
18
20
4. 60 2007.
90
80
80.2
75.4
80.1
72.7
70
79.9
73.5
68.0
66.2
60
50
40
30
20
10
0
5. 2006.
: , (http://data.euro.who.int/hfadb/)
11
, . ,
. ,
[27, 28].
. , ,
.
.
. ,
,
.

:
, ,
, .
, ,
:
() ;
;
, ,
;
, , , , , , ().

.
, ,
:
, , ;
,
(
, , ,
).

6, 7 8.
12
. .

200
183,1
182
183,1
180
160
140
166,9
172,6
163,4
147,5
144,7
175,3
156,3
176,6
164,4
168,8
162,5
153,8
160,3
140,4
146,4
143,7
120
123,1
124
126
100
80
60
40

20
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
6. (60-69) 19982008.

200
179,4
180
160
140
120
151
153,8
141,7
178,9
173,4
154,1
175,7
155,9
146
141,3
138
160,1
149,8
129,5
130,8
100
139
127
122,8
120
122,3
97,6
80
60
40

20
0
10
11
7. (60-69) 19982008.
13
3539

4000
4044
4549
3500
5054
5559
3000
6064
6569
2500
7074
7579
2000
8084
85
1500
1000
500
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
8. (60-69) 19982008.

(20-25) . , :
,
,
,
.
, , , , . , , 25% [29].
:
1. .
2. , , ,
. ,
(
).
3. , ,
14
. .
, .
4. ,
.
5. , , .
, [2, 21].
MONICA ,
2020.
128% 137% , 29% 48%
[30].
( 6% ), [17].
, . 2% . ,
[18].
9-15.

1200
1000
800
600
400
200
0
039
4044
4549
5054
5559
6064
6569
7074
75
9.
20062008.
15

10000
1000
467,35
164,36
535,24
786,64
239,09
262,74
100
411,46
1113,13
1226,01
563,59
650,51
1245,5
898,91
144,99
79,16
12,67
38,48
10
5,32
1
039
4044
4549
5054
5559
6064
6569
7074
75
10. 20062008.

180
160
140
120
100
120,6
119,7
110,3
129,5
80
129,9
123,9
140,8
124,9
155,3
118
125,8
138,8
145,8
130,9
134,9
129,3
142,9
120,6
122
127,9
138,4
67,5
60
40

20
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
11. (20-25)
19982008.
16
. .

250
200
174,1
173,4
185,1
194,4
178,7
158
169,1
166,2
164,4
154,5
150
89,4
100
107,6
119,6
109,8
119,4
120,2
97,5
89,4
50
102,8
96,5
71
51,6
1998.
1999.
2000.

2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
12. (20-25)
19982008.

90
80
83
76,5
70
60
72,9
71
73,4
69,4
63,9
68,8
68,6
77,2
67,6
70,9
61,9
50
70,3
63,1
69,9
69,2
65
64,5
58,7
60,8
61,9
40
30
20

10
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
13. (21)
19982008.
17

120
110,5
106,3
100
98,2
98,4
95,3
89
87,7
86,7
86,4
77,4
80
82,4
60
55,5
45,9
40
51,2
58,5
54,8
41
45
41,2
44,5
44,5
34,4
20

1
10
11
14. (21)
19982008.

3500
3000
2500
3539
4044
4549
5054
5559
6064
6569
7074
7579
8084
85
2000
1500
1000
500
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
15. - 2008.
18
. .
2007.
23%, 43%.
. 2006.
4,8% ( 3,1%, 5,4%, 10%), [16, 22].
(, ,
). ,
. , , 19901999. 50%,
, [17, 30, 31].

. , , , , , , , , [6, 15, 18].
60% ( DALYs
Disability-Adjusted Life Years;
) : (12,8%), (12,3%), (10,1%), (8,7%), (7,8%), (4,4%) (3,5%) ( 4).
4. (DALY/1000 ) ; , 2000.

DALY/1000
35,2
12,5
21,7
17,5
3,1
1,7
5,7
1,5
14,9
12,2
19,5
16,3
: The Burden of Disease and Injury in Serbia. Belgrade: Ministry of Health of the Republic of Serbia; 2003
19
()
. (, , .)
- , (, , ), [31, 32, 33].
2000. , 2006. 6,9%,
7,2% 12%. 2% 1% [16, 22]. 5 16.
5. (%) 2000.
2006.

2000.
2006.
69,0
57,8
23,9
27,7
52,6
40,2
45,9
46,7
17,1
38,7

2000.
2006.
40,5
33,6
44,5
46,5
47,5
40,3
17,3
18,3
13,7
25,7
: , (2000. 2006. )
100
90
80
70
60
50
40
30
20
10
0
16.
20062008.
20
. .

, , , , . ,
, [34].
, ,
, , . ,
, (. ),
, [2, 3]. , , [34].

. . ,
, . , :
1. .
;
2. , ;
3. , ;
4.
;
5.
;
6.
;
7. .
, . , ; 50% , [16, 18].
21
6. 2000. 2006.
(%)

2000.
2006.
77,5
79,5
47,7
57,6
28,8
35,2
67,3
50,1
42,0
54,7
37,4
43,6

2000.
2006.
71,9
56,6
43,4
57,2
40,5
33,8
62,7
48,7
42,5
54,8
34,4
44,0
( 6)
2000. 2006. . , 2000. .
2006. 33,8% 2000. (40,5%).
2006. 54,8%, 44,0% , 2000. (42,5%, 34,4%).
. , . .

, 25 [2, 17].

, ,
. , . , [10, 14].
, ,
,
, ,

22
. .
[29].
. .
, , , ,
.
, [2, 14].

, . .
. ,
. , [2, 21].
,
.
:

? ,
. , .
.
, , . , [3, 8, 15].
, , . , .
, , , , 5% 20% , .
23
, .
, . ,
[2, 8, 15].

. ,
. ,
. , ,
[2, 8].
.
, ,
, .
. . [6, 15].

,
.
:
)
;
) ;
) , ,
;
) ,
, .
? , , .
24
. .
, , ( , ,
), .
, , , , [2, 17].
. 350 (35 ) , 210 (21 ) . , [12, 16, 18].
, , [35]. , , , . . , , . , 10 (1 ), [17].
,
. , .
. ,
. , -, , ,
, [2, 17].
. ,
, [36].
. .
, 6, 12 .
, [37, 38].
,
,
[2].
25

, .
.
:
1. , . LDL ( )
;
2. HDL ( )
;
3. ,
;
4.
;
5.
65 , ;
6. , .
.
. . . , .
:
( LDL),
60-80% ; LDL , ;
, ,
;
( HDL), , 20-30% ; HDL , .
. 2,8 mmol/l,
6,2 mmol/l.
:
5,2 mmol/l;
5,26,4 mmol/l;
6,4 mmol/l.
5,2 mmol/l [28]. 6,5 mmol/l,
26
. .
. . 4,14 mmol/l.
4,145,17 mmol/l
( ). 6,92 5,85 mmol/l , 6,81 5,56 mmol/l .
1,7 mmol/l. 1,8-2,2 mmol/l
, 2,3 mmol/l .

,
()
. ,
, .
:
1. ,

, ;
2. ;
3.
, , , ;
4. ,
, .
, , ,
. , , , , . [28].
(,
), 50% . , . , . , , , [8, 9].

. , . ,
27
. [2, 17].

, , , .
.

[2, 28].
140 mm Hg, 80 mm Hg [6].
80
mm Hg 30 , , .

17.
. , , , , ( ), ( ).

40

35
30
25
32,4
26,5
15
15
16,6
10
16,3
17,8
12,7
10,7
5
0
21,7
17,8
14,7
8,3
6,5
1998.
1999.
2000.
32,9
25,9
20,2
20
31,8
25,9
23,3
26,8
31,9
2001.
2002.
2003.
2004.
2005.
2006.
9,9
2007.
2008.
17.
(10-15) 19982008.
28
. .
,
. 30-40% . 35 .
(90%
). ( , , ).
:
1. 20-80%
;
2. , ,
;
3. ,
;
4. ,
;
5.
;
6. ;
7. .
, , , . 50 .
, , , ,
, [3, 28].
. . , , , ( , ) [9, 18].
,
76% . ( 26%). 73%, 17% 63%, ,
[29].
29
24% 33% . ,
, . 2006.
6,9% 2000. , 33,6%.
9,8%, 3,8% [20, 22]. 3544 (46,9%), (36,7%), (36,7%) (39,9%) [20, 22].
,
. 2006. (61,7%) , 44,9% , 2000. . (62,1%), (49%). , 2034 3544 . , [39, 40].

. , .
:
1. .
;
2. , , , . .
3. , , .
, .
(. Body Mass Index BMI), . , BMI :
20 kg/m2 ;
2025 kg/m2 () ;
2530 kg/m2 ;
3040 kg/m2 ;
40 kg/m2 .
.
30
. .
(. waisthip ratio WHR). WHR 0,95 0,85 .

.
LDL-, HDL-. .
. BMI 12% .
, . 2, ,
[41].
. - , ,
, .
, [42].
2006. ,
719
(67,7%). (18%) ,
2000. . , (6,2%) 2000. (8,4%).
, .
(54,5%). 36,2% 110 g/l,
29,4% (31,9% 26,9% ) [16].
,
, , . , , . , .
:
31
1. , ;
2. ;
3. ;
4. .

.

. ,
. 2. 1
. 2 .
[43].
LDL. 2.
, . .
, , [43].

. , . . , , , , [45].
:
1. . ;
2. ;
32
. .
3. , , ;
4. , ;
5. ,
, , .
, ,
, ,
. , ,
, . .
. ,
,
.
.

.
, 1,9 . , , 2 . , , , .

; HDL, LDL . , ,
.
2,
.
. 70% .
,
,
.
30 [2, 45].
33

(
) . , .
. , . , , , .
.
: , [45].

, , . . ( ) .
3.000 . 2.
. .

. . ,
.
[46].

.
34
. .
7.
2000. 2006. (%)

2000.
2006.

78,4
16,0
5,6
81,8
14,8
3,4
76,8
13,2
10,0
67,6
17,7
4,6
82,8
5,7
11,6
82,0
11,2
6,8
71,5
16,0
12,5
70,8
18,0
11,2
82,7
7,9
9,4
78,8
10,7
10,4
90,5
2,5
7,0
83,5
2,9
13,6
95,8
0,5
3,6
92,7
1,5
5,8
89,7
3,8
6,5
79,8
8,3
11,9
. , ,

( , , ),
[46].

7. 16% 2000. , 14,8% 2006.
[16]. 13,2% 2000, 2006. 17,7%.

: , , , , , , , ,
.
:
1. , ;
2. ;
3. .
35
;
.
,
, , , . 55. 1,66 1,93 . .
2,6 100.000 36-44 , 1.417
100.000 75 [47]. ,
. , NHANES, 0,5% 20-39 , 12-15%
80 [14].
(1,15 1,3),
.
. [48].

. ,
. ,

[49]. , ,
[24].

, ,
. , , . .
1,6
36
. .
.
[50].
. 160/95 mm Hg,
140/90 mm Hg . . 10 mm Hg
1,9 1,7 . ( ). - . [51].

1,7 . , : , , , ,
, .
,
.
. 60-65% [52, 53].
, . , , 4,85 , 2,53 1,24

.
2,9 , 1,9
0,7 .
,
2-4 [2, 51].
37

,
. , ,

, . ,
( )
. , 2,96 [17, 52].

. , , .

[45, 54].

, , .
.
,
, , , , . [2]:
1. .
;
2.
;
3. ;
4. , ;
5. .

. , , , -
38
. .

. , , , .
,
, , 100 500
100.000 ,
[47, 51]. ,
, , . 300 2.000 100.000 , 3.000 13.000
65 .
, 25%
38% . , 15 28% 61% [47, 51].

, - ,
[55, 56].

, . , , .
, [29].
23-55 100.000 2-14 , 1.000 .
. ,

1-10% .
. 1-78 1.000 [14, 57].
.
. 3% . , . , 50% [58].
39
. 50% , [58].

. .
, , 1.000 . , ,
, , . [55].
. , 1,4-16,1%. 25-30% . , 10%
.
. , 80% .
.

, , , , , . , , , -,
[14].

,
, , [55].

,
40
. .
.
[2].
. .
, , .
:
( );
( );
( , ).
;
8% .
, , .
, , . [17].

1998 2008.
( ) , , - ( 8 9). ( , SO2, NO2 ) .

( ) , , - (e 10-13).

- , NO2, , 65 , ,
, , ,
.
41

( ) , - ( 14).
,
-
, , ,
, , , .
, . , , .

. ,
.
, ,
.
8. , - ; , 19982008.
r
0,609
0,630
-0,673
-0,675
-0,727
0,665
0,755
0,950
0,791
0,679
0,727
-0,673
-0,664
-0,786
-0,686
-0,709
-0,736

SO2
1.000
1.000

1.000

SO2
NO2

60

1.000
p
0,047
0,038
0,023
0,032
0,011
0,026
0,007
0,000
0,004
0,022
0,011
0,023
0,026
0,021
0,029
0,015
0,015
r ( , ); p
42
. .
9. , - ; , 19982008.
r
0,670
-0,627
-0,636
-0,738
-0,673
-0,873
-0,743
0,709
0,736
0,833
0,817
0,882
0,627
0,636
0,774
-0,622
-0,668
-0,759
-0,759
-0,764
-0,745
-0,685
0,753
-0,724
-0,756
-0,881
-0,825
-0,938
-0,606
-0,726

1.000
1.000

1.000
1.000

1.000
1.000
p
0,024
0,039
0,035
0,037
0,033
0,000
0,009
0,015
0,010
0,010
0,004
0,000
0,039
0,048
0,005
0,041
0,025
0,011
0,011
0,006
0,013
0,029
0,007
0,012
0,007
0,004
0,003
0,000
0,048
0,017
r ( , ); p
10. ; , 19982008.

NO2

65

B
1,949
-49,272
-0,236
764,760
-3,83-02
193,071
SE
0,265
0,727
0,003
10,791
0,000
31,970
1,711
-3,802
-7,348
3,865
-10,760
1,718
t
7,367
-67,819
-75,410
70,868
-90,958
6,039
p
0,005
0,009
0,008
0,009
0,007
0,009
B ; SE ;

43
11. ; , 19982008.

NO2

65

B
0,256
-5,466
-8,68-03
32,584
-79,877
SE
0,009
0,138
0,000
1,099
1,114
1,059
-1,990
-1,276
0,777
-1,595
t
29,336
-39,679
-24,454
29,660
-71,715
p
0,022
0,016
0,026
0,021
0,009
12. ;
, 19982008.

B
-5,226
SE
1,461
-1,607
t
-3,576
p
0,037
13. ; , 19982008.

NO2

65

B
0,548
-4,649
-3,74-03
24,721
-72,348
SE
0,005
0,084
0,000
0,667
0,676
1,149
-0,857
-0,278
0,298
-0,731
t
103,533
-55,566
-17,333
37,055
-106,947
p
0,006
0,011
0,037
0,17
0,006
14. : / ; , 19982008.
SE
-3,771-02
0,012
-0,747
-3,180
0,013
-3,197-03
0,001
-0,693
-2,271
0,026
3,737-03
0,001
0,664
2,511
0,036
0,002
-0,777
-3,491
0,008
/
/

-6,503-

, , , .
44
. .
, , ,
[10, 21, 23]. , , , ,
.
, . , . , , , [6, 8, 11].

, . , , [18].
. 1998-2008., . . .
1.
2.
3.
4.
5.
6.
7.
8.
9.
Pavlovi D, Mladenovi S, Koci S, Radovanovi S, Milosavljevi M. Karakteristike zdravstvenog stanja odraslog stanovnitva na teritoriji umadijskog okruga. Zdravstvena zatita. 2010;
5:65-9.
Luepker RV, Lakshminarayan K. Cardiovascular and cerebrovascular diseases. In: Oxford
Textbook of Public Health. 5th ed. New York: Oxford University Press; 2009. p.971-96.
oki D, Jakovljevi , Jakovljevi D. Socijalna medicina. Kragujevac: Medicinski fakultet
Univerziteta u Kragujevcu; 2007.
Mili , Radovanovi S, Koci S, onovi N. Navike u ishrani dece i omladine. Med Pregl. [in
press].
Koci S, Mili , Radovanovi S. Karakteristike korienja stacionarne zdravstvene zatite starih u KBC Kragujevac (19992002). Zdravstvena zatita. 2006; 1:19-24.
World Health Organization. Preventing chronic diseases: a vital investment. WHO global report. Geneva: WHO; 2005.
Popovi P, Mili , Koci S, Radovanovi S. Vanbolniki morbiditet stanovnitva Grada
Kragujevca. Zdravstvena zatita. 2009; 1:29-35.
Centers for Disease Control and Prevention. Chronic Diseases. Notes & Reports. 2007; 18(2).
World Health Organization. Gaining Health. The European Strategy for the Prevention and
Control of Noncommunicable Diseases. Copenhagen: WHO; 2006.
45
10. Miovi P, oki D, i sar. Zdravstveno stanje stanovnitva Srbije od 1986. do 1996. analitika
studija. Beograd: Institut za zatitu zdravlja Srbije Dr Milan Jovanovi Batut; 1997.
11. Grozdanov J, Gruji V, oki , Jelaa P. Razvoj zdravstvenog sistema, mesto i uloga zavoda za
zatitu zdravlja. Glasnik Zavoda za zatitu zdravlja Srbije 1997; 71:35-40.
12. Atanaskovi-Markovi Z, Bjegovi V, Jankovi S, Kocev N, Laaser U, Marinkovi J, et al. The
Burden of Disease and Injury in Serbia. Belgrade: Ministry of Health of the Republic of Serbia;
2003.
13. Vui-Jankovi Mila, Dimitrijevi D, Radovi Lj. Kardiovaskularne bolesti u SR Jugoslaviji.
Monografija. Beograd: Savezni zavod za zatitu i unapreenje zdravlja; 1996.
14. Heart Disease and Stroke Statistics. 2009 Update: A Report From the American Heart
Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;
119:e21-e181.
15. Chronic diseases. Available from: http://www.who.int/topics/chronic_diseases/en/.
16. oki D, Ili M. Zdravlje stanovnitva umadijskog okruga. Analitika studija 1998-2008.
Kragujevac: Institut za javno zdravlje Kragujevac; 2009.
17. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. WHO MONICA Project.
Stroke incidence, case fatality, and mortality in the WHO MONICA Project. Stroke. 1995;
26:361-7.
18. Luepker RV, Arnett DK, Jakobs DR Jr, Duval SJ, Folsom AR, Armstrong C, et al. Trends in blood
pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med.
2006; 119:42-9.
19. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. Recent trends in acute coronary heart disease mortality, morbidity, medical care, and risk factors. The
Minnesota Heart Survey Investigators. N Engl J Med. 1996; 334:884-90.
20. Jankovi S, Vlajinac H, Bjegovi V, Marinkovi J, ipeti-Grujii S, Markovi-Deni Lj, et al. The
burden of disease and injury in Serbia. Eur J Public Health. 2007; 17:80-5.
21. Murray CJL, Lopez AD, editors. The Global Burden of Disease: A comprehensive assessment of
mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020.
Global Burden of Disease and Injury Series, Vol. 1. Cambridge, MA: World Health Organization,
Harvard School of Public Health and World Bank; 1996.
22. Zdravlje stanovnika Srbije Analitika studija 19972007. Beograd: Institut za javno zdravlje
Srbije Dr Milan Jovanovi Batut; 2008.
23. American Heart Association. Heart Disease and Stroke Statistics 2007 Update. Dallas, TX:
AHA; 2008.
24. World Health Organization Regional Office for Europe. European mortality database (MDB).
Available from: http://data.euro.who.int/hfamdb/.
25. Fenomen starenja stanovnitva i politiki odgovor. esti gerontoloki kongres Jugoslavije:
Starenje i starost, za bezbedni i aktivni ivot. Zbornik uvodnih saoptenja. Beograd:
Gerontoloko drutvo Srbije; 2002. p.39-48.
26. Panev G. Struktura stanovnitva po polu i starosti. U: Stanovnitvo i domainstva Srbije prema
popisu 2002. godine. Beograd: Republiki zavod za statistiku Srbije, Institut drutvenih nauka
Centar za demografska istraivanja, Drutvo demografa Srbije; 2006. p.109-138.
27. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of hearth failure: the Framingham
Study. J Am Coll Cardiol. 1993; 22(4 Suppl A):6A-13A.
28. oki D. Kvalitet zdravstvene zatite i ishod kod arterijske hipertenzije. Beograd: Institut za
socijalnu medicinu, statistiku i istraivanja u zdravstvu Medicinskog fakulteta Univerziteta u
Beogradu; 1999.
29. WHO. World Health Report 2004: Changing history. Geneva: WHO; 2004.
30. WHO MONICA Project. Multinational monitoring of trends and determinants in cardiovascular disease. Geneva: WHO; 1994.
46
. .
31. Allender S, Peto V, Scarborough P, Kaur A, Rayner M. Coronary Heart Disease Statistics 2008.
London: British Heart Foundation; 2008.
32. Radna grupa za kardiovaskularne bolesti Nacionalnog komiteta za izradu vodia klinike
prakse u Srbiji. Prevencija ishemijske bolesti srca. Nacionalni vodi klinike prakse. Beograd:
Ministarstvo zdravlja Republike Srbije; 2002.
33. Vucic-Jankovic Mila. Epidemiological aspects of economic crisis in the FR Yugoslavia. APTH 98,
Second Asia-Pacific Travel Health Congress, Abstracts, Taipei, Taiwan, 1998.
34. Gaji I, oki D, Dovijani P. Politika hrane i ishrane u teoriji i praksi. Glasnik Zavoda za zatitu zdravlja Srbije. 1997; 71:210-8.
35. Radovanovi S, Koci S, Milovanovi N. Konzumiranje alkohola kod srednjokolske dece.
Materia Medica. 2008; 24(4):21-4.
36. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled
trial. JAMA. 2004; 291:565-75.
37. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al; Heart Outcomes Prevention
Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in
vascular disease. N Engl J Med. 2006; 354:1567-77.
38. Bonaa KH, Njolstad I, Ueland PM. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006, 354:1578-88.
39. Deletovi A, Rajevi M, oki D, Tomi V, Risti P, Dimitrijevi Z, et al. Unapreenje zdravlja zajednice uloga zavoda za zatitu zdravlja u sprovoenju primarne zdravstvene zatite. Glasnik
Zavoda za zatitu zdravlja Srbije. 1997; 71:41-7.
40. Matovi-Miljanovi S, oki D. Razvoj i uloga indikatora zdravlja u vezi sa ivotnom sredinom.
Glasnik Zavoda za zatitu zdravlja Srbije. 1997; 71:233-6.
41. Krauss RM, Wonston M, Fletcher RN. Obesity: impact of cardiovascular disease. Circulation.
1998; 98:1472-6.
42. Paisey RB, Harvey P, Rice S, Belka I, Bower L, Dunn M, et al. An intensive weight loss programme
in established type 2 diabetes and controls: effects on weight and atherosclerosis risk factors
at 1 year. Diabet Med. 1998; 15:73-9.
43. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from
cardiovascular causes. N Engl J Med. 2007; 356:2457-71.
44. Popovi R, oki D, Dovijani P. Sadraj rada i organizacija koordinativnih centara za unapreenje zdravlja u primarnoj zdravstvenoj zatiti. Zdravstvena zatita. 1997; 26(5):17-21.
45. Hu FB, Stampfer MJ, Colditz GA, Ascherio A, Rexrode KM, Willett WC, et al. Physical activity and
risk of stroke in women. JAMA. 2000; 283:2961-7.
46. Muller JE. Kaufmann PG, Luepker RV, Weisfeldt ML, Deedwania PC, Willerson JT. Mechanisms
precipitating acute cardiac events: review and recommendations of an NHLBI workshop.
National Heart, Lung, and Blood Institute. Mechanisms Precipitating Acute Cardiac Events
Participants. Circulation. 1997; 96:3233-9.
47. Hu HH, Sheng WY, Chu FL, Lan CF, Chiang BN. Incidence of stroke in Taiwan. Stroke. 1992;
23:1237-41.
48. Brown RD, Whisnant JP, Sicks JD, OFallon WM, Wiebers DO. Stroke incidence, prevalence, and
survival: secular trends in Rochester, Minnesota, through 1989. Stroke, 1996; 27:373-80.
49. Howard G, Howard VJ; REasons for Geographic And Racial Differences in Stroke (REGARDS)
Investigators. Ethnic disparities in stroke: the scope of the problem. Ethn Dis. 2001; 11:761-8.
50. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of
the genetic epidemiology of ischemic stroke. Stroke, 2004; 35:212-27.
51. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular
47
52.
53.
54.
55.
56.
57.
58.
48
exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med. 1993;
329:1677-83.
Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al; Stroke Prevention
in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med. 2003; 138:831-8.
Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;
37:1969-74.
Kiely DK, Wolf PA, Cupples LA, Baiser AS, Kannel WB. Physical activity and stroke risk: the
Framingham Study. Am J Epidemiol. 1994; 140:608-20.
Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;
39:1890-900.
Cohn JN. The managment of chronic heart failure. N Engl J Med. 1996; 335:490-8.
PAHO Fourth Meeting of the Working Group of Prevention of Rheumatic Fever. Quito, Ecuador,
1970.
WHO. Rheumatic Fever and Rheumatic Hart Disease. Technical Report Series, No 923. Geneva:
WHO; 2004.
. .
,

. , . ,
. , . ,
. , . .
, .
. , .
21. . , . , , , .

, ,
. , , .

,
. , , ,
( ),
( ).
[1].

.

() . a
[1-4].
49
. .
- , , , [1].
,
. , . , , [5].

. ,
() . (International
Classification of Diseases Oncology) .
: .
. , ,
,
, .
, , , . , . , [1, 6].
[7]. ,
:
,
,
,
,
,
.
:
) , ;
50
. .
)
( ), ;
) ,
.
. (International Agency for Research on Cancer IARC) . :
1 (101 );
2 ;
(69 );
2 (245 );
3 .

(), 2002. 10.860.000 , 5.800.000
5.060.000 . 24,6 . 2020. 11 16 ,
. , ,
, , , , , . , 2002.
6.720.000 [6, 8].
. 50 . ,
. ,
35 15. 50. [9, 10].
150.000 ,
32.000 20.000 (
1). (75%) (60%). [11].
, ( 59,088
DALY); (26,007 DALY), (23,868 DALY),
(16,487 DALY) (8,230 DALY). DALY ,
[12].
51
1. (00-97)
19982008.
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
17183
9759 (56,8%)
7424 (43,2%)
17376
9870 (56,8%)
7506 (43,2%)
17873
10179 (57,0%) 7694 (43,2%)
17917
10175 (56,9%) 7742 (43,0%)
18548
10635 (57,3%) 7913 (43,2%)
18859
10690 (56,7%) 8169 (42,7%)
19602
11109 (56,7%) 8493 (43,3%)
19741
11169 (56,6%) 8572 (43,4%)
20217
11495 (56,9%) 8722 (43,1%)
20417
11736 (57,5%) 8681 (42,5%)
20573
11810 (57,4%) 8763 (42,6%)
208306
118627 (56,9%) 89679 (43,1%)
645
633
689
667
684
697
694
749
718
792
777
7745
367 (56,9%)
278 (43,1%)
349 (55,1%)
284 (44,9%)
408 (59,2%)
281 (40,8%)
374 (56,1%)
293 (43,9%)
401 (58,6%)
283 (41,4%)
410 (58,8%)
287 (41,2%)
374 (53,9%)
320 (46,1%)
409 (54,6%)
340 (45,4%)
405 (56,4%)
313 (43,6%)
459 (58,0%)
333 (42,0%)
441 (56,8%)
336 (43,2%)
4397 (56,8%)
3348 (43,2%)
2000. 2006.
, .
2000. , 2006.
48,9%, 45,7%, 32,5%,
5,6% 1,9% ( 1, 2 3).
, 20002006. ( 2 4), , 7,6% ( 74,6 68,9 100.000 ). 30,9%, 9,9%, 6,3%,
1,1% [12].

, , , , .
. ,

. , ,
(, ) [13, 14, 15].
2006. , , . 75
[16, 17].
,
. ( 29 ) (),
; . (30-49 ) , ,
52
. .
360
329,1
340
320
306,9
304,6
300
337,1
287,2
284,4
289,2
280,1
280
260
256,7
240
220
200
236,1
1999.
258,1
258,2
266,1
258,6
261,7
243,5

2000.
2001.
2002.
2003.
2004.
2005.
2006.
1.
19992006.
400
349,1
350
324,2
315
312,1
300,9
322,8
297,2
324,3
300
309
291
284,9
273,4
250
200
349,8
256,7
1999.
2000.
2001.
263
263,4

2002.
2003.
2004.
2005.
2006.
2.
19992006.
53
80
60
40
20
1999.
2000.
2001.
2002.

2003.
2004.
2005.
2006.

3.
19992006.
80
60
40
20
1999.
2000.
2001.
2002.

2003.
2004.
2005.
2006.

4.
19992006.
54
. .
150
145
143,9
146,5
141,0
140
132,9
133,0
134,2
144,1
142,0
137,8
135,2
135
143,8
141,5
134,9
137,1
135,9
135,3
132,7
130
131,0
130,7
125
127,2
125,7
124,9

120
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
5.
19982008.
70
60
50
40
30
20
10
0
1998.
1999.
2000.
2001.
2002.
2003.

2004.
2005.
2006.
2007.
2008.

6.
19982008.
55
174,5
180
170
160
173,9
166,6
163,8
160,6
150,8
159,5
156,0
144,4
150
160,5
153,3
140
130
121,0
118,4
120
113,6
110,0
110,0
112,2
110
100
99,0
97,6
98,1
98,4
95,4

90
80
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
7.
19982008.
30
25
20
15
10
1998.
1999.
2000.
2001.
2002.
2003.

2004.
2005.
2006.
2007.
2008.

8. 19982008.
56
. .
, , , , .
50 , , , , [18].
19982008.
, ( 5 6).
32,4%, 16,0%, 15,0% 12,4%.

, , 16,7% ( 7 8). 43,8%, 9,4%, 4,1% 1,8% [17].

,

. 70%
. .
, . , , . , ( , , , ) , , , ( 2). , , [1, 18, 19].
. 30% . 2530% .
, , 87-91% 57-86% . , 43-60%,
.
, , , , , .
, .
57
.
(. ), .

, .
: .
, , [1, 18].
, ,
( ). , , [20, 21]. , , , , , , ( ) ( ). -.
,
[22, 23].
,
, , , , .
, [24].
1,5% 2% 35% . , 2-5%. , ,
[25, 26].

, ,
[24].
1,5-2%.
[27, 28].
58
. .
2.

(%)

2733
48
46
1
415
01
15
15
1535
1020
01

(%)
30
6
<1
<1
1
<1
<1
<1
2
<1
<1
: Doll&Peto 2005
3. IARC

16
, , , ,
18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66
6, 11
,
1
2
(
I)
(
II)
, , ,
,
,
, ,
8
Helicobacter pylori
Schistosoma haematobium
Schistosoma japonicum
Schistosoma mansoni
Opisthorchis viverrini
Opisthorchis felineus
Clonorchis sinensis
59

,
, , , , ( ) [29]. 3,6%, [30]. , 6% [31]. .

, , . IARC 3.
, 17,8% . ,
()
1.
60
: CDC
. .
(Helicobacter pylori) 20-30%

. , 26,3%,
7,7%.
,
, ,
( 1).

40 IARC. (-),
, , ;
2-3% [31].
, ,
, 1% ,
, . , ,
, [32, 33].

, . , .
, . . , . .
[34, 35].

IARC, ,
, ,
61
, , , . , 3-5% [36].
( ) , 90%
,
1%. ,
, [1].

. , .
.
.
.

, , [37].
. [38].

, .
, , .
2% 4%, [1, 7].

, ,
, , ,
. . , , [39].
62
. .
. , ,
, .
, [40].

, , .
- , , . - , .
,

100%. 1-10 1.000 ; 95%, 5% , [37].
,

, 930.000
2002. 8,5% [41].
15 100.000 25 100.000
, ,
. : 78/100.000,
33/100.000. ,
, . , - .
, .
, . .
.
63
, , , , ,
.
. . , -, , .

[42]. , . , , . .
Helicobacter pylori.
, . , 50% [36].
. 50-60%
.
. , .
, ( ).
12,9 100.000
,
6,5 ( 4 5).

, 11,2, 5,9 100.000 ( 6 7).

,
. , . ,
. ,
. ,
.
64
. .
, 2002. 1.020.000
, 530.000 [42].
, (
) ( 30/100.000, 25/100.000). 15
4.

(-10)
(34)
(18-20)
(61)
(67)
(16)
(32)
(71)
(91-95)
(25)
(00-10)
(22)
(64)

(00-97)

2875
1591
1045
781
617
524
401
306
302
296
294
263
3055
11594
(1/100.000)
108,4
60,0
39,4
29,4
23,3
19,8
15,1
11,5
11,4
11,3
11,1
9,9
114,9
465,5
(ACP World)
63,6
33,6
19,6
16,2
12,9
12,1
11
6,5
6,4
6,4
6,4
6
67
298,3
: , . 5. , 2006.
5.

(-10)
(50)
(18-20)
(53)
(34)
(54)
(56)
(16)
(67)
(71)
(25)
(22)
(91-95)

(00-97)

2864
1095
1004
878
633
459
383
286
267
240
217
207
3079
11594
(1/100.000)
101,7
39,1
35,9
31,4
22,6
16,4
13,7
10,2
9,5
8,6
7,8
7,4
110,2
414,5
(ACP World)
60,4
38
24,8
16,7
12,7
10,1
6,5
5,2
7,2
4
3,9
3,6
64,2
240,7
: , . 5. , 2006.
65
100.000 . , 1,5:1, , . , [43].

6.

(-10)
(34)
(18-20)
(61)
(16)
(25)
(22)
(32)
(67)
(71)
(91-95)
(64)
(15)

(00-97)

2183
855
578
556
355
320
310
308
283
203
149
134
1421
7655
(1/100.000)
82,3
32,2
21,8
21
13,4
12,1
11,7
11,6
10,7
7,7
5,6
5,1
53,3
288,5
(ACP World)
47,1
17,2
11,4
11,2
7,4
6,9
6,7
6,6
5,6
4,9
3,2
2,8
31,7
161,8
: , . 5. , 2006.
7.

(-10)
(50)
(34)
(18-20)
(53)
(16)
(25)
(56)
(22)
(71)
(91-95)
(67)
(54)

(00-97)

1085
676
654
355
303
277
250
198
186
141
93
81
1533
5832
(1/100.000)
40,9
25,5
24,7
13,4
11,4
10,4
9,4
7,5
7
5,3
3,5
3,1
57,7
219,8
(ACP World)
24
14,4
12,9
8
5,9
5,4
4,7
4,2
4
2,8
1,3
1,2
31,4
122,4
: , . 5. , 2006.
66
. .
, . , .
, ,
[20]. . ,
, , [44].
.

[45].
[45]. , . , , .

. 5-20, , .
.

(1,5-2 ), .

, , , , 1 2, .
, . , ( 20/100.000, 10/100.000) [46].
.

, 33,6, 38,0 100.000 ,
( 4 5).

, 17,2 100.000 , 12,9 100.000 ( 6 7).

, , ,
67
, [47].
, , .
.
50 .

. , , , .
, . 40 100.000 10 100.000 ,
. 5/100.000 2,5/100.000 . 100.000 ,
- .
2002.
630.000, 80% (55% ) [42]. , 600.000.
11. , 6,4, 3,9 100.000 , ( 4 5).
,
6,9/100.000, 4,2/100.000 ( 6 7).
() ()
. (
), ,
. ,
, . , .
54%, 31% [36].

, , Aspergillus flavus Aspergillus parasiticus, .
68
. .
, , , [48].
. , [49]. , 1,52 [47].
, , [35].
. , .

. .
, , , .

,
,

. 960.000 ,
850.000 [42]. (5-10% ) [50, 51].

. . :
.
(
80/100.000) [52]. ,
.
, , , ,
. (
100.000 ) .
63,6/100.000,
16,7/100.000,
( 4 5).
69

,
47,1/100.000, 14,4/100.000 ( 6 7).

. ,
, , , . 16%, 10, 6, 3,
2% 60, 50, 40 30 [53].

. . , ,
, .
50% 60 [54].

[55].
,
, , . [56].
, , 5-10% .
, :
Mycobacterium tuberculosis . , . .
. . .

70
:
, ;
, ;
, ;
, .
. .
,
, .

, , , . 95% , .
, . .
.
, , , ,
.

. 160.000 [42]. 25 100.000
; ,
100.000 . , [46].
. .
, .
, ;
1,5-2 , 2-4 , . , . . .
[57].
, . , (
71
). .

80% , .
( 85%) . 50-60%.
.
2002. 640.000
510.000 [42]. 410.000 . , ( 20/100.000). (70-90/100.000) , , , [46].
,
.
,
[58]. , 30% 50%.
19601990. ,
.
60,4 100.000
( 5), .

,
24/100.000 ( 7).
, [59]. [60]. , . , . . 47 4,3% .
.
72
. .
(25% ). ,
[61].
,
[62].

,
,
.
, , [21].
[44]. 60. , 30-50%.
. . . - . 1%
, , .
,
[45].

50 , -, , .

( )
, . , ,
(20-40/100.000). , (5-15/100.000) [46]. 370.000
, 78% , , .
230.000 , . , . 60. ,
73
50. .
.
24,8
100.000 ( 5), .

,
8/100.000 ( 7).
. () . 5-40% . ,
( 16, 18, 31 45).
(Chlamydia, Herpex simplex 2).
( ,
). , .
.
( )
, . , , . 16, 18, 6 11, , 16 [63].

, , ,
, , . 2002. 200.000 ,
. 50.000 .
(10-15/100.000),
, ( 100.000). .
- , [64].
. ,
. ,
74
. .
. , ,
, [27, 34].
(2-10
). 50-100% . , , . , .
12,7 100.000 ( 5), .
12. , 1,2/100.000 ( 7).
.

,
() . 2002.
200.000 , 125.000 .
(10-12/100,000), . ( 100.000).

, 10,1
100.000 ( 5), .

,
4,7/100.000 ( 7).
,
[65].
,
;
, 40% . 15-20 ,
[66].

, . ,
75
3-5 . . - BRCA1 17q BRCA2 13q, .

,
(100/100.000). , (20-40/100.000),
(5/100.000). 2002.
680.000 ,
220.000 , 60% .
( )
, .
BRCA1 BRCA2
- . 8q24 17q12,
[67].
,
.
,
, ,
[68].
,
,
.
19,6 100.000 ( 4), .
, 11,4/100.000
( 6).

.
.
76
. .

50% .
,
.
, , . , , , , , ,
[69].
.
, , , . , .
, .
90% .
, . ,
50% , ,
.
. 1998-2008., . . .
1.
2.
3.
Boffeta P, La Vecchia C. Neoplasms. In: Oxford Textbook of Public Health. 5th ed. New York:
Oxford University Press; 2009. p.997-1020.
Petrovi M, Ili N, Lonarevi O, ekerevac I, Lazi Z, Novkovi Lj, et al. Faktori rizika za pojavu metastaza u mozgu u hirurkom IIIA stadijumu nemikrocelularnog karcinoma plua nakon
hirurkog i hemiozranog leenja. Vojnosanit Pregl. 2011; [in press].
Petrovi M, Ili N, Baski D. Znaaj neuroendokrinih markera u odgovoru na leenje i preivljavanje bolesnika s odmaklim nesitnoelijskim karcinomom plua. Srp Arh Celok Lek. 2010;
138(1-2):37-42.
77
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
78
orevi M, Mitrovi S, orevi G, Jovanovi B. Endometrioidni tumor ovarijuma i uterusa,

metastaza ili ne prikaz bolesnika. Acta Medica Medianae. 2008; 47(2):33-7.
Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, et al. A major lung
cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet. 2004; 75:460-74.
Beaglehole R, Bonita R, Kjellstrom T. Basic Epidemiology. Geneva: WHO; 1993.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
Radovanovi S, Koci S, Mili . Mortalitet od malignih neoplazmi na teritoriji umadijskog
okruga. Zdravstvena zatita. 2005; 5:41-6.
Radovanovi S. Mili , Koci S, onovi N. Uestalost i rasprostranjenost malignih neoplazmi.
Zdravstvena zatita. 2009; 2:33-40.
Vui-Jankovi M, Trajkovi-Pavlovi Lj. Mortality caused by carcinoma in Yugoslavia and in the
world. Archive of Oncology. 1996; 4(Suppl 2):26.
Institut za javno zdravlje Srbije Dr Milan Jovanovi Batut. Zdravlje stanovnika Srbije
Analitika studija 1997-2007. Beograd: Institut za javno zdravlje Srbije Dr Milan Jovanovi
Batut; 2008.
Institute of Public Health of Serbia. Attributable Causes of Cancer in Serbia 2005. Belgrade:
Institute of Public Health of Serbia; 2008.
Incidencija i mortalitet od raka u Centralnoj Srbiji 2003. Registar za rak, Izvetaj br. 5. Beograd:
Institut za javno zdravlje Srbije; 2006.
Vlajinac H, Jankovi S, ipeti-Grujii S. Cancers. In: The Burden of Disease and Injury in Serbia.
Belgrade: Ministry of Health of the Republic of Serbia; 2003. p.94-102.
Radovanovi S, Mili , Koci S, Gajevi G. Uestalost i rasprostranjenost malignih neoplazmi
na teritoriji umadijskog okruga. Medicinski asopis. 2007; 1(Suppl 1):37.
Incidencija i mortalitet od raka u centralnoj Srbiji 19992006. Registar za rak centralne
Srbije. Beograd: Institut za javno zdravlje Srbije; 2008.
oki D, Ili M. Zdravlje stanovnitva umadijskog okruga. Analitika studija 19982008.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence
and mortality in Europe in 2006. Ann Oncol. 2007; 18:581-92.
Marques-Vidal P, Ravasco P, Ermelinda CM. Foodstuffs and colorectal cancer risk; a review. Clin
Nutr. 2006; 25:14-36.
Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB. Diet and brest cancer:
a review of the prospective observatonal studies. Cancer. 2007; 109:2712-49.
Trajkovi-Pavlovi Lj, Dimitrijevi D, Vui-Jankovi M. Ishrana kao faktor rizika za nastanak
raka dojke ene. VIII kongres preventivne medicine Jugoslavije sa meunarodnim ueem.
Zbornik rezimea. Beograd; 1995.
Trajkovi-Pavlovi Lj, Vui-Jankovi M, Dimitrijevi D. Nain ishrane i smrtnost od malignih
neoplazmi odreenih lokalizacija u SR Jugoslaviji. Monografija. Beograd: Savezni zavod za zatitu i unapreenje zdravlja; 2000.
IARC Handbooks of Cancer Prevention. Weight Control and Physical Activity. Vol. 6. Lyon: IARC
Press; 2002.
Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer
in Europe. Int J Cancer. 2001; 91:421-30.
Doll R, Peto R. Epidemiology of cancer. In: Oxford Textbook of Public Health. 4th ed. New York:
Oxford University Pres; 2005. p.193-218.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined estrogenprogestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC
Monogr Eval Carcinog Risks Hum. 2007; 91:1-528.
. .
29. oki D. Kvalitet zdravstvene zatite i ishod kod arterijske hipertenzije. Bepgrad: Institut za
socijalnu medicinu, statistiku i istraivanja u zdravstvu, Medicinski fakultet Univerziteta u
Beogradu; 1999.
30. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al.; WHO International Agency
for Research on Cancer Monograph Working Group. Carcinogenicity of alcoholic beverages.
Lancet Oncol. 2007; 8:292-3.
31. Boffetta R. Human cancer from environmental pollutants: the international chemoprevention
trials. Mutant Res. 2006; 608:157-62.
32. Boyle P. European Code Against Cancer and scientific justification: third version. Ann Oncol.
2003; 14:973-1005.
34. orevi M, Mitrovi S, Jovanovi B, Sazdanovi P, Foli M, Mitrovi M, et al. Expression of
estrogen and progesterone receptors in subcutaneous endometriosis. Archives of Biological
Sciences. 2010; 62(3):547-51.
35. Damjanov V, Niki D, Vajagi L, oki D. Uloga zavoda za zatitu zdravlja u unapreenju i zatiti ivotne sredine. Glasnik Zavoda za zatitu zdravlja Srbije. 1997; 71:112-6.
36. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Household use of solid fuels and high-temperature frying. IARC Monogr Eval Carcinog Risks Hum. 2010; 95:1-430.
38. orevi M, Jovanovi B, orevi G. Operative treatment of endometriosis in the Clinical
Centre of Kragujevac during the period 20042008. Med Glas Ljek komore Zenicko-doboj kantona. 2010; 7 (2):166-9.
39. Baski D, Ili N, urevi P, Risti P, Avramovi D, Arsenijevi N. In vitro induction of apoptotic cell death in chronic lymphocytic leukemia by two natural products: preliminary study. J
BUON. 2010; 15:732-9.
40. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J
Cancer. 2006; 118:3030-44.
41. Miovi P, oki D i sar. Zdravstveno stanje stanovnitva Srbije od 1986. do 1996. analitika
42. Plummer M, Vivas J, Lopez G. Chemoprevention of precancerous gastric lesion with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst.
2007; 99:137-46.
43. Ferlay J, Bray F, Pisani P, Parkin M. GLOBOCAN 220: Cancer Incidence, Mortality and Prevalence
Worldwide. IARC CancerBase No. 5, Version 2.0. Lyon, France: IARC Press; 2004.
44. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review
(Unated States). Cancer Causes Control. 2005; 16:83-95.
45. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update quantitative review to 2005.
Cancer Causes Control. 2006; 17:871-88.
46. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer incidence in five continents. Volume VIII. IARC Sci Publ. 2002; (155):1-781.
47. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and
involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004; 83:1-1438.
48. London WT, McGlynn KA. Liver Cancer. In: Cancer Epidemiology and Prevention. New York:
49. La Vecchia C. Alcohol and liver cancer. Eur J Cancer Prev. 2007; 16:495-7.
79
50. Petrovi M, Ili N, Tomi I, Jovanovi D. Neuroendocrine differentiation in non-small cell lung
cancer and its relation to prognosis and therapy. Lung Cancer. 2009; 64(1):S32-3.
51. Tomi I, Petrovi M, Plavec G, Ili S. Influence of chemotherapeutic protocol and neuroendocrine differentiation on metastatic non-small cell lung cancer treatment results. Vojnosanit Pregl.
2007; 9(64):591-6.
52. IARC Handbooks of Cancer Prevention. Fruit and Vegetables. Vol. 8. Lyon: IARC Press; 2003.
53. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ.
2000; 321:323-9.
54. Gauderman WJ, Morrison JL, Carpenter CL, Thomas DC. Analysis of gene-smoking interaction
in lung cancer. Genet Epidemiol. 1997; 14:199-214.
55. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Ionizing radiation,
Part I, X- and gamma- radiation and neutrons. IARC Monogr Eval Carcinog Risks Hum. 2000;
75(Pt 1):1-448.
56. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Ionizing radiation, part 2: some internally deposited radionucleides. IARC Monogr Eval Carcinog Risks Hum.
2001; 78(Pt 2):1-559.
57. Gruber SB, Armstrong BK. Cutaneous and ocular melanoma. In: Cancer Epidemiology and
Prevention. New York: Oxford University Press; 2006. p.1196-1229.
58. Vukievi A, Milju D, Djoki D. Prevencija hroninih nezaraznih oboljenja uloga zavoda za zatitu zdravlja. Glasnik. 1997; 71(Suppl):95-102.
59. Djordjevi M, Jovanovi B, Mitrovi S, Djordjevi G. Ectopic mammary tissue in vulva. Vojnosanit
Pregl. 2008; 65(5):407-9.
60. Colditz GA, Baer H, Tamimi RM, et al. Breast cancer. In: Cancer Epidemiology and Prevention.
New York: Oxford University Press; 2006. p.995-1012.
61. IARC. Agents classified by the IARC Monographs, Volumes 1-100. Available from: http://monographs.iarc.fr/ENG/Classification/index.php.
62. Stefanick ML, Anderson GL, Margolis KL. Efects of conjugated equine on breast cancer
and mammography screening in postmenopausal women with hysterctomy. JAMA. 2006;
295:1647-57.
63. Clifford GM, Gallus S, Herrero R, Muoz N, Snijders PJ, Vaccarella S, et al.; IARC HPV Prevalence
Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically
normal women in the International Agency for Research on Cancer HPV prevalence surveys: a
pooled analysis. Lancet. 2005; 366:991-8.
64. orevi M, Mitrovi S, Jovanovi B, orevi G. Ovarijalna metastaza kod pacijentkinje sa endometrijalnim karcinomom ili sinhroni tumori prikaz sluaja. Med Pregl. 2010; 63(7-8):570-3.
65. Hankinson SE, Danforth KN. Ovarian cancer. In: Cancer Epidemiology and Prevention. New
York: Oxford University Press; 2006. p.1013-26.
66. La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer: an update. Drug
Saf. 2001; 24:741-54.
67. Gudmundsson J, Sulem P. Two variants on chromosome 17 confer prostate cancer risk, and the
one in TCF2 protects against type 2 diabetes. Nat Genet. 2007; 39:977-83.
68. Platz EA, Giovannucci E. Prostate cancer. In: Cancer Epidemiology and Prevention. New York:
69. Ross JA, Spector IG. Cancers in children. In: Cancer Epidemiology and Prevention. New York:
80
. .
,

. , . . . -,
.
( ) . : 1,
,
; 2, 85-95% , . 250 ( 6% ),
, , 2 . 70% , . 15
1 10 2,
, . . , 2007. 2,1%
. 2 60% . 1 . , , , , . , . 21. , 2006. .
,
(. diabetes mellitus)
. ,
, . , . .
16. . 18.
81
. 1869. , , 1956. [1, 2].
(-10: 10-14, -24)

, . , . , - . ,
, , - . . [2, 3].
() .
,
( ). - , .
- , , .
.
. , , , , . (). , , ,
. ,
, (). , [2].
-. 90% . 40 ( 65. 74. )
. , , [3].
82
. .
.
: - - . [1, 2].
1979, 1980. (American Diabetes Association ADA) () , . 1, ,
2,
, . 2 .
, 2006. , , 1 [4].
( ) . , (. oral glucose tolerance test OGTT).
1.

, :
- ( 1),
- ( 2),
,
,
.
1 -
, , . -,
1. ( ) OGTT 120.

<6,1 mmol/l (<110 mg/dl)
6,1-7,0 mmol/l (110-126 mg/dl)
7,0 mmol/l (126 mg/dl)

(
) 11,1 mmol/l (200 mg/dl)

(, ,
)

OGTT
<7,8 mmol/l (<140 mg/dl)

7,8-11,1 mmol/l (140-200 mg/dl)
11,1 mmol/l (200 mg/dl)
83
,
, - .
2 . 90% , .

. . 24. ,
. , . ,
, 20-50% 2.

. ,
, . ( - ), , (, , ), , , . 30-40% , [1, 2].

. : -, , (
), (. ), , .

.
. ( ) HbA1c ( ). 6%
, , ,
.
.
84
. .

( )
. (
) 3,9-6,1 mmol/l.
, . .

OGTT
. . , 150-200
( ). 75 200 , . .
6,7
mmol/l, 7,8 mmol/l. 11,1 mmol/l . .
:
50 , , ,
150 , , , , , , .

, .

.

. : ( ), , - .

. ,
85
. ,
, , .
:
() , ; ;
; , , ;
, , , ;
() , ;
;
, , , , ;
;
;
;
.

(International Diabetes Federation IDF),
.
.
[5].
2 .
, ,
, .
2-5%; ( 1%),
( 50%). , 3%,
( 7%). 90%
2 [5, 6, 7].
, .
.
2007. 246 , 3,7% ,
86
. .
5,9% 20 79 .
2, 85-95% [8].
,
. 13 40-59 ,
70 . ,
[8].
IDF 2025.
380 . (
),
, . [9, 10].
, 70-80% , , , [11].
, 2. [8]. ,
[12, 13]. , , [14, 15].
.
,
[16].

[17, 18].
IDF 500.000 6,7% . 1, 2 (95%). , 2 [19, 20]. , 65 [21].
1, , ( ), . 2,
, 1
, 5-14 [22,
23]. 9% 20%
87
. ,
. , [23, 24]. 1 HLA . DR3, DR4 . ,
. , [25].
. 1
11. 13. ,
,
.
1.
, 14 20/100.000,
1/100.000, , [25].
1

-.
(, , 4), , - [26].
1986. 1996. , 7%, 3%, . ,
, . . , [7, 27].
, . [28]. [29, 30].
2 , 45 . , ,
[31].
. 20-25% . 15-20
88
. .
. , , 70% .
2 8-10 .
[32, 33].
1 35,3
100.000 . . , , , , .
. 1, , , 2 [34, 35].
2008. 540 2. -
150 ( 1). , , IDF, [27, 28, 36].
, .
, 50% 2 [20, 21].

185.000 . 12,3% 25-74
800
690,8
700
600
519,4
495,6
500
400
373,4
386,5
324,9
300
200
135,0
76,1
100
0
0,0
0,0
9,4
0,0
16,6
27,1
0,0
0,0
04
59 1014 1519 2024 2529 3034 3539 4044 4549 5054 5559 6064 6569 7074 75
1. - 2
2008.
89
. (15,5%), (9,5%).
25-34 0,4%, 65-74
21,6%. (19,8%) (10,1%).
[37].

2000. , , ,
[36, 38].
[19]. 3.000 . 100 . 19982008.
( 2,2% 2,8%).
, 1997. ,
2008. , , , [27, 28].
2008.
3,1% 124 (41 83 ). 19982008. , ( 2),
[27, 29].

( 3) [34].
1998. 2008. (61,6%) ( 4).
87,6%. , , , ( ). 45-49 . 2008.
1998. 30,4%, 63,2%
( 5).

1 3% , 5% .
70.000 15 1 ( 200 ).
440.000 14 ,
25% , 20% .
2 50%
15 . , , . 2
90
. .
35
29,8
30
26,0
25
25,8
23,2
27,3
26,7
25,2
25,4
23,0
22,7
25,6
23,9
24,7
25,2
23,7
27,8
27,7
23,1
21,0
19,2
20
18,3

15
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
2. 19982008.

1998.
2007.
10
15
20
25
30
3. 1998. 2007.
: (http://data.euro.who.int//hfadb/)
91
35
33,6
31,3
30
29,7
27,1
25
26,6
25,5
24,9
23,4
20
25,6
24,4
25,5
24,5
23,3
22,9
20,1
19,0
18,1
19,7
22,2
18,8
17,5
18,0
15

10
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
4. 19982008.
300
250
269,4
200
208,5
162,1
148,4
150
115,4
100
99,2
65,2
50
46,9
0,0
0
04
-50
0,0
0,0
0,0
0,0
0,0
0,0
0,0
5,5
4,6
0,0
3,8
23,8
11,5
17,4
13,1
59 1014 1519 2024 2529 3034 3539 4044 4549 5054 5559 6064 6569 7074 75

-100
5. -
1998. 2008.
92
. .
43% , 29% . 2 20 1.
2 [30].
.
, , . , , [31, 32].
[29], 2007. 143 14 1.
14,3,
. ,
14 .
9,3, [28, 29].

. 14. IDF.
2007. . IDF, 2008.
.
. , .
, , . ,
.
, , , , . :
,
,
,
, , , , ,
( ).
2 .
1 . ,
15 . , , 2 . [26].
93

. .
,
. , (. , , , ).
. 2, 1.
1

. - , , . ,
,
[39].
1 6%, 0,4% ( ) . , 50%. (HLA) 1, ,
90% 1
. , ,
, [39, 40].

1
,
, [39, 40].
1 , (, ). ,
94
. .
1; [41]. , , , . [41, 42].

-
90%
1, - (ICA), GAD (-) IA2 (-).

, .
1
,
[43].
2
. : , , .
; , , [3].

2 .
,

.

2 . .
95
, 70% [44].
. .
( )
. , .
, .
90% , ,
70% [45].
2-5% . . (, ). , , .

2. , , [16].

2 , 60% .
, , , .
70% [46].
, , - ( ). , . [46].
2
. 30-50% [47]. ,
( ) [48].
96
. .
2 [49].
2,
50% [50].

2
. . , ,

[51].

2 [52].
( , , , , HDL-) 2 [53].
2
() ,
. ,
. ,
, (, , ), , .
.
97

, ,
. . ,
(. ).
,
, .

2009. [28]
19982008.
; . , 2. (
) .
,
- , ,
, 65 , , ( 3).
, - .
, , , .

2. , -
19982008.
r
0,712
0,725
0,794
p
0,014
0,012
0,019
r ( , ); p
98
. .
3.
19982008.

65

B
-4,937
1,672-03
25,064
-10,233
SE
0,356
0,000
0,420
0,388
-0,362
0,429
1,044
-0,357
t
-13,855
28,135
59,744
-26,407
p
0,046
0,023
0,11
0,024
B ; SE ;
. ,
. , , , ,
.

.
20-29 , ,
70-79 . 40-80% .
[54].

. 2
, ,
. 60
[55].
1 .
15 , ,
25 15. .
1 [56].
, . 5-10% .
99

: , , .

, . , .
. , , , , - , .
, , , , . , , . , , . , .

; - , , .

, , , .
.
.
, , , , .
, .
, , , , .
,
. : , .
.
100
. .

5 mmol/l. 30%.
, ,
.
, , , . . , .
, 2,8 mmol/l.
, .
(Whipple) :
, 2,8 mmol/l
. , , , , , , , ,
, , , .
. .

: , , , , .

, .
, [57]. 50% . , 59% 74%
[54, 55].
101
:
, , ;
, , , ;
, , ,
;
, , ;
, .

25 . 25 , 1 .
, 75% [57, 58]. 2, 40-60%
, 10% . [59].
,
50 100.000 . 1, 2 .
.
: .
, , . ,
, , .

.
, , .
, 1, 7-10
. .
, .
102
. .

; 40-50%
, 15-33% [60].
,
1 2 ; 30%
.
2, 1 [60].
.
. .
.
, , .
.
. , , .

, , , , , [61].
. ,

. ,
.
(
), , , ,
( ) . , , ,
, , , .
103
: , , ,
, .
. ,
, , .

, . 15% , 5-15% . ,
40-60% [62].

. 1, 2 30% .
50% [63].
. 18% 2 , 11% , [64, 65].

. , , .
, , [66].
IDF, 2007. 4,4-8,8 , 6,1-10,9 , 14,8-26,9 119,3-213,8
104
. .
. ; - [66].
. , 2 65 7% .
0,4% , 2,1% 1,2% [67].

1 . , . - [39].
2 , . , , ,
50-60% [68].
, ,
[69].
,
, . 24.155
: 1)
25 kg/m2; 2) 30% ; 3) 10%
; 4) 15 1.000 ; 5) .
.
, . 20% [70].
, , .

,
,
105
4. 2

( )

,

,

( , , )
,
,

,

,

, , . [71, 72].
2005. IDF ( 4),
2008.
, : .
, , , , , [73].
, , . , , . .
21. .

,
, , [74]. , -
. :
,
106
. .
,
,
( ),
,
,
,
,
.
,
() ,
, [74, 75].
, ( ), , .
:
,
,
,
.
. 2 ,
, .
. , , .
. : , , , , , . , (55-60% ), ( 30%), ( 300 mg
25 g/1000 kcal), (0,8 g/kg ), [75].
:
,
,
,
,
,
,
,
107
,
,
.

.
,
. ,
,
.
, : (710 ) ( 36 ).
, , (, , , ) .
,
.

, , 2 , , . ,
.

2 , : ( , ), .
,
.
:
,
,
,
,
,
,
108
. .
,
, .
() (, ). , , , , , , .
, . . .
.
.
,
,
, , .
,
.
(, , , ) . .

. , , .
, . ,
.
. 19982008., . . .
109
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
110
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care. 2003; 26(Suppl 1):S5-20.
Bennett P, Knowler W. Definition, diagnosis, and classification of diabetes mellitus and glucose
homeostasis. In: Kahn CR, Weir GC, King GL, Moses AC, Smith RJ, Jacobson AM, editors. Joslins
Diabetes Mellitus. 14th ed. Boston: Lippincott Williams and Wilkins; 2005. p.105-113.
Unvin N, Zimmet P. The epidemiology and prevention of diabetes mellitus. Oxford Textbook of
Public Health. 5th ed. New York: Oxford University Press; 2009. p.1068-80.
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate
hypoglycemia: report of WHO/IDF consultation. Geneva: WHO; 2006.
Aspray TJ, Mugusi F, Rashid S, Whiting D, Edwards R, Alberti KG, Unwin NC; Essential NonCommunicable Disease Health Intervention. Rural and urban differences in diabetes prevalence in Tanzania: the role of obesity, physical inactivity and urban living. Trans R Soc Trop Med
Hyg. 2000; 94:637-44.
Miovi P, oki D, i sar. Zdravstveno stanje stanovnitva Srbije od 1986. do 1996. analitika
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27:1047-53.
Popkin BM. The shift in stages of the nutrition transition in the developing world differs from
past experieces! Public Health Nutr. 2002; 5(1A):205-14.
Popkin BM, Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their
determinants. Int J Obes Relat Metab Disord. 2004; 28(Suppl 3):S2-9.
Unwin NC, Alberti KG. Diabetes and the good, the bad and the ugly of globalization. Int Diabetes
Monitor. 2007; 19:6-11.
Larraaga I, Arteagoitia JM, Rodriguez JL, Gonzalez F, Esnaola S, Pinis JA; Sentinel Practice
Network of the Basque Country. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetes complications in the Basque Country,
Spain. Diabet Med. 2005; 22:1047-53.
Kumari M, Head J, Marmot M. Prospective study of social and other risk factors for incidence of
type 2 diabetes in the Whitehall II study. Arch Intern Med. 2004; 164:1873-80.
Xu F, Yin XM, Zhang M, Leslie E, Ware R, Owen N. Family average income and diagnosed
Type 2 diabetes in urban and rural residents in regional mainland China. Diabet Med. 2006;
23:1239-46.
Popkin BM. The nutrition transition: an overview of world patterns of change. Nutr Rev. 2004;
6(7 Pt 2):S140-3.
Oldroyd J, Banerjee M, Heald A, Cruickshank K. Diabetes and ethnic minorities. Postgrad Med
J. 2005; 81:486-90.
Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In:
Diabetes in America. 2nd ed. Bethesda, MD: National Diabetes Data Group, National Institutes
of Health; 1995. p.47-67.
Gohdes D. Diabetes in North American Indians and Alaska natives. In: Diabetes in America.
2nd ed. Bethesda, MD: National Diabetes Data Group, National Institutes of Health; 1995.
p.683-701.
Egger G, Swinburn B. An ecological approach to the obesity pandemic. BMJ. 1997; 315:
477-80.
. .
20. Ylihrsil H, Lindstrm J, Eriksson JG, Jousilahti P, Valle TT, Sundvall J, et al. Prevalence of diabetes and impaired glucose regulation in 45- to 64-year-old individuals in three areas of Finland.
Diabet Med. 2005; 22:88-91.
21. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the
metabolic syndrome: a summary of the evidence. Diabetes Care. 2005; 28:1769-78.
22. McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P, et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med. 2004;
21:318-23.
23. International Diabetes Federation. Diabetes Atlas. 3rd ed. Brussels: International Diabetes
Federation; 2006.
24. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of
childhood type 1 diabetes worldwide. Diabetes Mondiale (DabMond) Project Group. Diabetes
Care. 2000; 23:1516-26.
25. Knip M, Veijola R, Virtanen SM, Hyty H, Vaarala O, Akerblom HK. Environmental triggers and
determinants of type 1 diabetes. Diabetes. 2005; 54(Suppl 2):S125-36.
26. LaPorte RE, McCarty D, Bruno C, Tajima N, Baba S. Counting diabetes in the next millennium.
Aplication of capture-recapture technology. Diabetes Care. 1993; 16:528-34.
27. Institut za javno zdravlje Srbije Dr Milan Jovanovi Batut. Zdravlje stanovnika Srbije
Batut; 2008.
28. oki D, Ili M. Zdravlje stanovnitva umadijskog okruga. Analitika studija 19982008.
29. Incidencija i mortalitet od dijabetesa u Srbiji 2007. Registar za dijabetes u Srbiji. Beograd:
Institut za javno zdravlje Srbije; 2008.
30. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS
36): prospective observational study. BMJ. 2000; 321:412-19.
31. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care,
2004; 27(Suppl 1):S5-S10.
32. Jarrett RJ. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. In:
Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, editors. International Textbook of Diabetes
Mellitus. Chichester, New York: Wiley; 1992. p.1459-70.
33. Levy-Marchal C, Papoz L, de Beaufort C, Doutreix J, Froment V, Voirin J, et al. Incidence of juvenile type 1 (insulin-dependent) diabetes mellitus in France. Diabetologia. 1991; 33:465-9.
34. European Health for all Database (HFA-DB). Copenhagen: WHO Regional Office for Europe;
2009.
35. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silinik M; Consensus Workshop Group.
Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004; 27(7):1798-1811.
2003.
37. oki D. Kvalitet zdravstvene zatite i ishod kod arterijske hipertenzije. Beograd: Institut za
socijalnu medicinu, statistiku i istraivanja u zdravstvu, Medicinski fakultet Univerziteta u
Beogradu; 1999.
38. Venkat Narayan KM, Zhang P, Kanaya AM, Williams DE, Engelgau M, Imperatore G, et al.
Diabetes: the pandemic and potential solutions. In: Venkat Narayan KM, Zhang P, Kanaya AM,
editors. Disease Control Priorities in Developing Countries. Boston: Lippincott Williams and
Wilkins; 2005. p.591-603.
39. Gillespie KM. Type 1 diabetes: pathogenesis and prevention. CMAJ. 2006; 175:165-70.
40. Knip M. Risk factors of envoronmental for diabetes type 1. BMJ. 2006; 50:125-30.

111
41. Couper JJ. Environmental triggers of type 1 diabetes. J Pediatr Child Health. 2001; 37:218-20.
42. Rewers M, Zimmet P. The rising tide of childhood type 1 diabetes what is the elusive envoronmental trigger? Lancet. 2004; 364:1645-7.
43. Kukko M, Kimpimki T, Korhonen S, Kupila A, Simell S, Veijola R, et al. Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred
risk of type 1 diabetes recruited from the general population. J Clin Endocrinol Metab. 2005;
90:2712-7.
44. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study
identifies novel risk loci for type 2 diabetes. Nature. 2007; 445:881-5.
45. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005; 115:485-91.
46. Vazquez G, Duval S, Jacobs DR Jr, Silventoinen K. Comparison of body mass index, waist circumference and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol
Rev. 2007; 29:115-28.
47. Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care. 2007; 30:744-52.
48. Lindstrm J, Peltonen M, Eriksson JG, Louheranta A, Fogelholm M, Uusitupa M, et al. High-fibre,
low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish
Diabetes Prevention Study. Diabetologia. 2006; 49:912-20.
49. Smith B, Wingard DL, Smith TC, Kritz-Silverstein D, Barrett-Connor E. Does coffee consumtion
reduce the risk of type 2 diabetes in individuals with impaired glucose? Diabetes Care. 2006;
29:2385-90.
50. Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE. Smoking and incidence of diabetes
among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care.
2005; 28:2501-7.
51. Phillips DW, Jones A, Goulden PA. Birth weight, stress, and the metabolic syndrome in adult life. Ann N Y Acad Sci. 2006; 1083:28-36.
52. Unwin N, Shaw J, Zimmet P, Alberti KG. Imparied glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002; 19:708-23.
53. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic
syndrome a new worldwide definition. Lancet. 2005; 366:1059-62.
54. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality
attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005; 28:2130-5.
55. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with
diabetes and impact of material deprivation: longitudinal, population based study. BMJ. 2001;
322:1389-93.
56. Nishimura R, Laporte RE, Dorman JS, Tajima N, Becker D, Orchard TJ. Mortality trends in type
1 diabetes. The Allegheny County (Pennsylvania) Registry 1965-1999. Diabetes Care. 2001;
24:823-7.
57. Klein R, Klein BEK. Vision disorders in diabetes. In: Diabetes in America. 2nd ed. Bethesda, MD:
National Diabetes Data Group, National Institutes of Health; 1995. p.293-338.
58. Roy MS, Klein R, OColmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophtalmol. 2004;
122:546-51.
59. Klein R. The epidemiology of diabetic retinopathy. In: Pickup J, Williams G, editors. Textbook
of Diabetes. London: Blackwell Scientific Publications; 1997.
60. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005; (94):S14-8.
61. Little AA, Edwards JL, Feldman EL. Diabetic neuropathies. Pract Neurol. 2007; 7:82-92.
62. Edmonds M, Boulton A, Buckenham T, Every N, Foster A, Freeman D, et al. Report of the Diabetic
Foot and Amputation Group. Diabet Med. 1996; 13(9 Suppl 4):S27-42.
112
. .
63. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and
duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002;
25:1458-63.
64. Nichols GA, Brown JB. Unadjusted and adjusted prevalence of diagnosed depression in type 2
diabetes. Diabetes Care. 2003; 26:744-9.
65. Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;
27:2154-60.
66. Williams R. Medical and economic case for prevention of type 2 diabetes and cardiovascular
disease. Eur Heart J. 2005; S7:D14-7.
67. Economist Intelligence Unit. The silent epidemic: An economic study of diabetes in developed
and developing countries. London: Economist Intelligence Unit; 2007.
68. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007; 334:299.
69. Lindstrm J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemi K, et al.; Finnish
Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes
by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;
368:1673-9.
70. Simmons R, Harding AH, Jakes R, Welch A, Wareham NJ, Griffin SJ. How much might achivement of diabetes prevention behaviour goals reduce the incidence of diabetes if implemented
at the population level? Diabetologia. 2006; 49:905-11.
71. World Health Organization. Obesity: Preventing and Managing the Global Epidemic Report
of a WHO Consultation on Obesity. Geneva: WHO;1997.
72. Willett WC, Koplan JP, Nugent R, Dusenbury C, Puska P, Graziano TA. Prevention of chronic disease by means of diet and lifestyle changes. In: Disease Control Priorities in Developing Countries.
2nd ed. Washington New York: World Bank, Oxford University Press; 2006. p.833-850.
73. Venkat Narayan KM, Zhang P, Kanaya AM, Williams DE, Engelgau MM, Imperatore G, et al.
Diabetes: the pandemic and potential solutions. In: Disease Control Priorities in Developing
Countries. 2nd ed. Washington New York: World Bank, Oxford University Press; 2006.
p.591-603.
113
114
. .
,

. , . ,
. , . ,
. , . .
() , , . , . , , .
, . , , . , . .
, , , , , , , , , . , ,
. . 21. (
)
.
. , , () . , .
,
[1, 2].
115
, . . , , . , (. ) [3, 4].
(-10: 42-44) (-10: 45) (; -10: 42-45). 400
, 320 , 80 .
2006. ,
.
, 320.000 , 200.000 [5, 6, 7].
27%: 19,48/100.000
1998. 24,77/100.000 2008. .

1998. 2000. 2002. 2004. ,
2001, 2005, 2006. 2008. ( 1).
. 19982008.
(30,96%) (16,24%) ( 2).
25,12%,
23,79%. 40%, 8%
( 1).
, : 38,4% 37,15% ;
15,05% 14,14% ( 2).
. (99%), (56,5%)
(51,9%), (0,2%), (2,6%) (8,3%)
( 3).
-
(303,16%) ( 75 ),
70-74 (118,83%) 65-69 (104,29%). 40-44 (5,54%),
40 ( 4).
, ( 5). ( 6).
116
. .
29,3
28
26
29,1
27,2
28,1
27,3
26,9
26,1
24,5
25,5
28,9
24,8
25,6
24
21,5
22,5
22
19,5
22,7
22,9
23,1
21,4
18,6
18
16

1998.
1999.
1. (; 42-45)
19982008.
48,3
44,9
44,4
41,7
37,7
33,6
43,8
36,6
31,9
29,1
18,8
17,9
14,7
14,6
16,7
15,6
13,5
15,1

1998.
1999.
2. 19982008.
117
56,5
51,9
8,3
2,6
3. 2006.
5,5
19,3
11,9
16,5
118,8
26,8
59 14 1519 24 2529 34 3539 44 4549 54 5559 64 6569 74 75
4. - 2008.
118
. .
111
75
86
82
81
83
73
73
66
55
55
52
111
96
88
115
112
95
129
123
55
46
38
39
33
37
23
41
33
26
1998.
1999.
5. 19982008.
2763
1693
1855
1794
1647
1443
897
2281
2192
892
2493
2398
2539
1475
969
1633
749
755
797
1499
947
1663
1722
887
918
782
1998.
1999.
6. 19982008.
119
3,5
3,2
3,1
2,8
2,8
2,7
2,7
2,6
2,5
2,7
2,6
2,6
2,5
2,3
2,2
2,4
2,4
2,3
2,5
2,4
2,2
2,2

1,5
1998.
1999.
7. 19982008.

,
0,73%. 2004. 2007. .

2,58%, 6% , 2,43%,
( 7).

[8]. 17. 18. , , ,
1814. . (1821) . 150 (1966) [8].

(Global Initiative for Chronic Obstructive Lung Disease GOLD), :
, ,
120
. .
.
, [9].
,
. ,
: ,
( ).
, [8].

,
.
, (. forced
vital capacity FVC), .
, (. forced expiratory volume in 1 second FEV1), , . , FEV1 FVC [9, 10].
, GOLD 2006. ,
:
1. (FEV180%);
2. (FEV1=50-80%);
3. (FEV1=30-50%);
4. (FEV1<30%), .
,
, , , . 2006.
, ,
1.
, ,

. , . , ,
[11].
121

:
) , , ;
) ;
)
.
[12].
,
19902004. ,
[11].
sthma, . , . , 17. [13].

() (Global Intiative for Asthma GINA) : ,
. , (), , ,
. , .
, . , [1, 9].

. ,
, ,
. ,
122
. .
. . ,
.
, , [1, 3].
.
, , . .
.
, .
. FEV1
12% 200 ml 2006. GINA . .
GINA :
; ; FEV1
je 80% , FEV1 20%;
, , ; ; FEV1 80% , FEV1 20-30%;
;
; ;
FEV1 60-80%, FEV1 30%;
; ; ; FEV1 60% , FEV1 30%.

. , .
123

, . . . ,
.
. .
( ) , . .
, . ,

[14].
,

, . .
, .
, ,
.
, . ,
.
, . , 80% , , (45%), (46%) (40%) [15]. , ,
. 39% , [15].
124
. .
, , ,
.
,
[16]. -1 (), , ( 1%).

,
.
, , [17].

( ), 2001. [12].

4% 11%, ,

.
[18, 19].
2000.
2,7 ,
. 400.000 . 0,5% 3-4% [20, 21].
1990
2004. 28 , 101
. 7,6%, 6,4% 1,8%. 8,9% [11].
,
. . ,
21/1.000 1994. 33/1.000 2015, 10/1.000 23/1.000
[22, 23].
, [2, 24].
125
: (42),
(43) (44).
, , [4].
, ( 90% ), [5, 6].
65%, 12,76
1998. 20,99 100.000 2008. , 2001.
2006. ( 8).
19,60 100.000 ,
19,98/100.000.
64%,
2% ( 8).
, , . , .
( 4,14% 12,16%), ( 23,54%
31,85%) ( 9).

, ( 10). , ( 11).
19982001. 20042006. , 2002. 2003.
( 12). 2007. . ,
( 13).
( 12).

. 2008. 40%
1998, ( 14).
( 15).

2006. 3,6% 4,9% . , ,
. , ,
, [5, 6].
126
. .
26
24
22,9
21,9
22
25,1
24,8
21,2
22,4
19,4
17,2
18
14
12
12,8
1998.
16,6

13,3
1999.
17,8
17,3
16
21,1
8. (; 42-44),
19982008.
45
33,9
32,5
35
39,7
38,1
31,9
29,9
25
23,5
25,9
25,1
23,6
16,2
15
11,8
12,6
11,6
12,1
11,1
9,8
13,4
12,2
4,5
4,1

1998.
1999.
9. 19982008.
127

1,64
1,48
1,5
1998.
1999.
10. (42)
19982008.

1998.
1999.
11. 19982008.

128
. .

1998.
1999.
12. (43) 1998

2008.

1998.
1999.
13. 19982008.

129
26
24,9
23,4
24
22,4
22
19,7
19,8
19,7
17,2
18
19,5
19,3
19,2
18,3
19,6
16,8
16,1
16
16,4
16,4
15,7
14
12

12,8
1998.
1999.
14. 19982008.
45
38,4
33,3
35
25,1
25
39,7
37,5
23,5
31,4
29,1
23,6
25,5
15
11,8
12,6
11,5
12,1
13,1
12,8
9,2
12,2
9,8
4,1
1998.

1999.
15. 19982008.

130
. .
. 45 , 65 . ,
, 2020.
[7].

(, ,
), , .
FEV1 [25].
, 73% ,
40% [20]. FEV1 ,
.
. 10,7% FEV1 .
,
,
[20].
,
[26].
[27].
,
25 27% ,
5,7% [28].

,
. ,
131
, FEV1
. (American Thoracic Society ATS) 2003. 15-20% , . [29].
(30%). , , (, ).

, ( ) [30]. , , 35% [20].

. , , . ,
[31].
, .
.
, .
,

, (IgE) 2
(Th2), 5 (IL-5)
,
.
.
, [32, 33].
132
. .

IgE . (, ),

in vivo in vitro. . - IgE
, ,

. , , . [34].
IgE
, , , -, . ,
;
,
, . , Th2
, - IgE.
,
, .
IgE ,
. , , , [1, 34].
(4-8 ) , Th2 , , IL-5. ,
. [1].
. , ,
.
133

. ,
, [35]. , ( ). ,
,
.
. , .

( ) 50%. , IgE , (60%)
[36]. , .
, [37].

[32] , :
,
,
,
.
. (, ) IgE ,
. , .
.
(
)
(, ), .

(IgE) e .
134
. .
, ( , ,
.)
[32].
, . . , , [33].

, .
.
. , , , [38].
,
.
. , 7-15 , , 1,3% 1974.
5,1% 1985. 5,8% 1991. .
,
[39].
,
. .
,
[40].

( 1),
( ) ( ,
IgE .) ( 2). , ECRHS (European Community Respiratory
Health Survey ) ISAAC
(International Study of Asthma and Allergies in Childhood ).
135
ECRHS 3.000 20. 44.

. ECRHS 1,
.
,

. 600 150 , , IgE , , , , , , [41].
48
(, , , , , ). 37 16 [42].
ISAAC ECRHS, 1
2 . ,
. 1 ( 155 56 ) 2, ,
, .
- , .
6-7 13-14 .

.
. 1, 700.000 , [43].
ECRHS ISAAC

. ?
1.
. , - ISAAC.
2. ISAAC .

. .
3. , . ISAAC
136
. .
- , , . , - , .
.
4. . , ,
, , .
, ,
. 12 10,1%,
, , 2%.
5. , , , , .
, , ,
(). ,
, , , . .
( )
,
.
6. 2 ISAAC . [37].
7. , . ISAAC 3 , 13-14 ,
,
(, ) [38, 43]. , 2 ECRHS
.
[42].
. , -.

. ,
137
8,3

8,7
9
8
7
6,7
5,5
6,4
6,2
5,4
4,3
5,8
4,1
3,8
3,7
4,2
3,6
2,4
3,3
3,2
2,5
2,3
1998.
1999.
16. (45) 19982008.
14
12,4

12
9,3
7,1
7,7
6,4
7,8
7,1
6,3
6,2
6,3
5,8
4,6
2,8
3,1
2,4
1,2
1998.
1999.
3,6
1,9
17. 19982008.
138
. .
. , . , - .
0,7 38,7 1.000 , . , . , .

2006. , 2,7% [5, 6]. 81%: 6,72
1998. 3,71 2008. ( 16).
2000. ( 2006. 2,01), . , ,
( 17). . , 58% ( 3,71, 2,35) ( 16).

ISAAC ECRHS,
, . ,
.
,
IgE , . 50%, ( 20%) [37, 44].
1 (IgE ) ,
1 . IgE ,
. , . , IgE ,
139
. , 20% 40% [36].

. . ,
( , ,
) . (, .).

.
. . , , ,
. .
, IgE IgE, .
,
. , , , .
. 7.000
. , 19% ,
[45].
,
2q, 5q, 6q, 12q 13q [46]. 5 (IL-4, IL-13, CD14 ADRB2), 6 (HLA-DRB1, HLA-DBQ1 TNF) 11 (FCER1B), . , ,
[46].
140
. .

,
, . , [47, 48].
, . , 12. , . .
. , IgE , .
, , .
.
, , . , , , [49].

. ,
. ,
, .
,
(, , ), , [50].
,
, ,
141
( ).
, [51, 52]. , .
. ,
[53, 54, 55].

[56].
,
14. 44. [57]. , ,
9-26 , [58].
[59, 60].
.

. , , , , ,
, ,
. n-3 ,
[61, 62].
( , -, )
. .

, - . .

. [63, 64].
142
. .

, , .
, , . 34. . ,
[65].
- 10
. -,
.
,
, . ,
[66]. [66].
,
. ,
,
.
, [67, 68].

( ) .
,
. ,
, .

. - , -
143
.
, .
, . , [69].

. . 28% .
, . 250 . 2-15%
, 15% , 5% , 2-3% 2-6%
.

, ( 75-85% ), (80-85%).
( 60% ) [70].
,
. .
. ,

. , . . , .
,
.
. ,
144
. .
.
80% [70].
()
, IgE , , , [71]. ,
,
, Th2 .
[72].
, , IgE
. .
[73].
,
, , , , . ,
.
.

.
, .

, , , . ,
. ,
, [74, 75]. 402 12-13 .
145
. 12-13
. [73].

2009.
19982008. , [5].
, 1.
1. , - 19982008.
(42)
(43)
(44)
(45)
-0,654
0,684
-0,800
-0,638
0,757
0,711
0,618
0,798
0,664
0,849
0,627
0,609
-0,609
-0,627
-0,738
-0,723
-0,782
-0,729
0,688
0,029
0,020
0,003
0,035
0,007
0,021
0,043
0,006
0,026
0,001
0,039
0,047
0,047
0,039
0,037
0,018
0,004
0,017
0,019
1.000
1.000

1.000
1.000

2
2
60
1.000

1.000
1.000
r ( , ); p
146
. .
2. 19982008.

B
-4,32-05
1.000
-1,65-02

-1,467
1,992-05

0,584

1,111-04
-2,32-04

9,087

-9,728

-0,376
SE
0,000
-0,876
t
-8,370
p
0,004
0,004
-0,440
-4,367
0,022
0,258
0,000
0,115
0,000
0,000
0,316
0,575
0,117
-0,594
0,875
0,360
0,846
-0,958
1,511
0,563
-0,627
-5,688
14,874
5,074
13,795
-18,295
28,761
16,919
-2,978
0,011
0,001
0,010
0,001
0,035
0,022
0,038
0,025
B ; SE ;
3. , - 19982008.

1.000
/

1.000
1.000

r
0,728
-0,636
-0,762
-0,698
-0,682
0,865
0,891
0,929
0,714
0,920
0,767
/
0,623
-0,800
-0,836
-0,952
-0,835
-0,973
-0,618
-0,706
-0,721
-0,676
p
0,011
0,035
0,028
0,025
0,021
0,001
0,000
0,001
0,020
0,000
0,010
/
0,040
0,003
0,001
0,000
0,003
0,000
0,043
0,023
0,019
0,032
147
( )
. 2 3
() , , .
( , CO2, 2, ) .
, , - .
, - ( 2 3).
,
- ,
, , ,
, .

?
, , .

,
.
,

.
. ,
, , . ,

[76]. ,
.
148
. .
, (), , ,
.
.

. ( , ) . , . (6,6%), (1,6%),
. (5,9%) (3,9%), . 19,2% , 7,3% [74].
;
. ,
.
, .

, . 5-34 , .
, . ,
, .
1910. 1960. ,
, ,
. , . , ,
. 1948. .
.
,
149
, , , , . .
, . ,
- () 1961. , .
.
,
. . ( , , , ) , . (, , ).
1976. , . , ,
, -, , ,

. , .

. 1976.
.
. 5%,
.

.
, .
5-45 19811983. . , , .
1989. , .
150
. .
-.

. ,
: 12 ,
. , 12 ,
, 20%.
.
, .
, .

,
. ,

.
[1].
- .
Th2 ,
, 4 5 , IgE . , Th1 , IgE
Th2 . -
, . Th2 . Th2 Th1 .
. . , Th2 , , . .
151
Th1-Th2
,

, . , , ,
, , . , , ,
. , . Th1-Th2 , .
,
,
.
Th1-Th2 , , . :
1. . , ,
. , .
, ;
2. . ,
, ;
3. , , , ,
,
. ,
. , , ,
;
4. . ,
152
. .
.
, ;
5. . . ,
. , .

. , , , , -, , , , .
. 21.
.
, , . ,
, . ,
. ,
, , .
. , 50% .

. .
153

, . .
.
, . , ,
(-).

1. , , .
2. , .
3. ,
.
4. ;
, .
5. , .
6. , , .
. 1998-2008., . . .
154
. .
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Douwes J, Boezen M, Pearce N. Chronic obstructive pulmonary disease and asthma. In: Detels
R, Beaglehole R, Lansang MA, Gulliford M, editors. Oxford Textbook of Public Health. 5th ed.
New York: Oxford University Press; 2009. p.1021-45.
Miovi P, oki D, i sar. Zdravstveno stanje stanovnitva Srbije od 1986. do 1996. analitika
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence and future trends.
Lancet. 2007; 370:765-73.
Institut za javno zdravlje Srbije Dr Milan Jovanovi Batut. Zdravlje stanovnika Srbije
Batut; 2008.
World Health Organization. WHO Strategy for Prevention and Control of Chronic Respiratory
Diseases. Geneva: WHO; 2002.
Petty T. The history of COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1:3-14.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al; Global Initiative for Chronic
Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med.
2007; 176:532-55.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al; ATS/ERS Task Force.
Standardisation of spirometry. Eur Respir J. 2005; 26:319-38.
Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD:
systematic review and meta-analysis. Eur Respir J. 2006; 28:523-32.
Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al. Epidemiology and
costs of chronic obstructive pulmonary disease. Eur Respir J. 2006; 27:188-207.
Keeney EL. The history of asthma from Hippocrates to Meltzer. J Allergy Clin Immunol. 1964;
35:215-26.
Pearce N, Beasley R, Pekkanen J. Role of bronchial responsiveness testing in asthma prevalence surveys. Thorax. 2000; 55:352-4.
Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, et al. Impact of COPD
in North America and Europe in 2000: subjects perspective of Confronting COPD International
Survey. Eur Respir J. 2002; 20:799-805.
Milosavljevi M, Radovanovi S, Koci S, Vasi M, Milovanovi N. Konzumiranje cigareta kod
srednjokolske omladine u gradu Kragujevcu. Medicinski asopis. [in press].
Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther. 2006; 111:476-94.
Vestbo J. COPD in the ECRHS. Thorax. 2004; 59:89-90.
ekerevac I, Lazi Z, Novkovi Lj, Petrovi M, Cupurdija V, Kitanovi G, et al. Exercise tolerance
and dyspnea in patients with chronic obstructive pulmonary disease. Vojnosanit Pregl. 2010;
67(1):36-41.
Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006; 27:397-412.
Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax. 2000; 55:789-94.
155
23. Watson L, Boezen HM, Postma DS. Differences between males and females in the natural history of asthma and COPD. Eur Respir Mon. 2003; 25:50-73.
24. Vestibo J. Epidemiology: Chronic Obstructive Lung Disease. Hamilton, Canada: BC Decker Inc;
2002.
25. Wang X, Mensinga TT, Schouten JP, Rijcken B, Weiss ST. Determinants of maximally attained level of pulmonary function. Am J Respir Crit Care Med. 2004; 169:941-9.
26. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the
true burden of disease? Chest. 2003; 123:1684-92.
27. Miravitlles M, de la Roza C, Naberan K, Lamban M, Gobartt E, Martin A, et al. Attitudes toward
the diagnosis of chronic obstructive pulmonary disease in primary care. Arch Bronconeumol.
2006; 42:3-8.
28. Lkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006; 61:935-9.
29. Balmes JR. Occupational contribution to the burden of chronic obstructive pulmonary disease.
J Occup Environ Med. 2005; 47:154-60.
30. Liu S, Zhou Y, Wang X, Wang D, Lu J, Zheng J, et al. Biomass fuels are the probable risk factor for
chronic obstructive pulmonary disease in rural South China. Thorax. 2007; 62:889-97.
31. Potsma DS, Weiss ST, editors. Genetics of Asthma and Chronic Obstructive Pulmonary Disease.
New York: Informa Healthcare USA; 2007.
32. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and
identification using induced sputum. Respirology. 2006; 11:54-61.
33. Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, et al. Pathological features and
inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;
62:1043-9.
34. Pearce N, Douwes J, Beasley R. The rise and rise of asthma: a new paradigm for the new millennium? J Epidemiol Biostat. 2000; 5:5-16.
35. Ronchetti R, Rennerova Z, Barreto M, Villa MP. The prevalence of atopy in asthmatic children
correlates strictly with the prevalence of atopy among nonasthmatic children. Int Arch Allergy
Immunol. 2007; 142:79-85.
36. Ili N, Velikovi V, Djoki D, Rankovi N, Kosti G, Petrovi M, et al. Klinike manifestacije atopije kod dece u prve dve godine ivota. Vojnosanit Pregl. 2011 [in press].
37. Weinmayr G, Weiland SK, Bjrkstn B, Brunekreef B, Brchele G, Cookson WO, et al; ISAAC
Phase Two Study Group. Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med. 2007; 176:565-74.
38. Pearce N, At-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al; ISAAC Phase Three Study
Group. Worldwide trends in the prevalence of asthma symptoms: phase III of the International
Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007; 62:758-66.
39. Bollag U, Capkun G, Caesar J, Low N. Trends in primary care consultations for asthma in
Switzerland, 1989-2002. Int J Epidemiol. 2005; 34:1012-8.
40. Pearce N, Douwes J. Commentary: asthma time trends mission accomplished? Int J Epidemiol.
2005; 34:1018-29.
41. Flohr C, Weiland SK, Weinmayr G, Bjrkstn B, Brbck L, Brunekreef B, et al; ISAAC Phase Two
Study Group. The role of atopic sensitization in flexural eczema: findings from the International
Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. 2008; 121:141147.e4.
42. Chinn S, Jarvis D, Burney P, Luczynska C, Ackermann-Liebrich U, Ant JM, et al. Increase in diagnosed asthma but not in symptoms in the European Community Respiratory Health Survey.
Thorax. 2004; 59:645-51.
156
. .
43. Asher MI, Montefort S, Bjrkstn B, Lai CK, Strachan DP, Weiland SK, et al; ISAAC Phase Three
Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006; 368:733-43.
44. Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax.
1999; 54:268-72.
45. Zamel N, McClean PA, Sandell PR, Siminovitch KA, Slutsky AS. Asthma on Tristan de Cunha: looking for the genetic link. The University of Toronto Genetics of Asthma Research Group. Am J
Respir Crit Care Med. 1996; 153(6 Pt 1):1902-6.
46. Bierbaum S, Heinzmann A. The genetics of bronchial asthma in children. Respir Med. 2007;
101:1369-75.
47. Pattemore PK, Ellison-Loschmann L, Asher MI, Barry DM, Clayton TO, Crane J, et al. Asthma
prevalence in European, Maori, and Pacific children in New Zealand: ISAAC study. Pediatr
Pulmonol. 2004; 37:433-42.
48. Radovanovi S, Koci S, oki D, Milisavljevi M, Popovi P, ivanovi S. Zdravstveno stanje kolske dece i omladine u umadijskom okrugu. Zdravstvena zatita. 2010; 6:1-7.
49. Redline S, Gold D. Challenges in interpreting gender differences in asthma. Am J Respir Crit
Care Med. 1994; 150(5 Pt 1):1219-21.
50. Ellison-Loschmann L, Sunyer J, Plana E, Pearce N, Zock JP, Jarvis D, et al; European Community
Respiratory Health Survey. Socioeconomic status, asthma and chronic bronchitis in a large
community-based study. Eur Respir J. 2007; 29:897-905.
51. Shore SA. Obesity and asthma: lessons from animal models. J Appl Physiol. 2007; 102:516-28.
52. Burney P. The changing prevalence of asthma? Thorax. 2002; 57(Suppl 2):ii36-9.
53. Brbck L, Hjern A, Rasmussen F. Body mass index, asthma and allergic rhinoconjunctivitis in
Swedish conscripts a national cohort study over three decades. Respir Med. 2005; 99:1010-4.
54. Bustos P, Amigo H, Oyarzn M, Rona RJ. Is there a causal relation between obesity and asthma?
Evidence from Chile. Int J Obes (Lond). 2005; 29:804-9.
55. Kosti G, Ili N, Petrovi M, Markovi S, Vuleti B, Igrutinovi Z. Indeks telesne mase dece sa
astmom pre i posle jednogodinje primene inhalatornih glikokortikoida. Med Pregl. 2010;
63(5-6):409-13.
56. Friedman NJ, Zeiger RS. The role of breast-feeding in the development of allergies and asthma.
J Allergy Clin Immunol. 2005; 115:1238-48.
57. Matheson MC, Erbas B, Balasuriya A, Jenkins MA, Wharton CL, Tank ML, et al. Breast-feeding
and atopic disease: a cohort study from childhood to middle age. J Allergy Clin Immunol. 2007;
120:1051-7.
58. Sears MR, Greene JM, Willan AR, Taylor DR, Flannery EM, Cowan JO, et al. Long-term relation
between breastfeeding and development of atopy and asthma in children and young adults: a
longitudinal study. Lancet. 2002; 360:901-7.
59. Kramer MS, Matush L, Vanilovich I, Platt R, Bogdanovich N, Sevkovskaya Z, et al; Promotion
of Breastfeeding Intervention Trial (PROBIT) Study Group. Effect of prolonged and exclusive breast feeding on risk of allergy and asthma: cluster randomised trial. BMJ. 2007; 335:815.
61. Devereux G. Early life events in asthma diet. Pediatr Pulmonol. 2007; 42:663-73.
62. Almqvist C, Garden F, Xuan W, Mihrshahi S, Leeder SR, Oddy W, et al; CAPS team. Omega-3 and
omega-6 fatty acid exposure from early life does not effect atopy and asthma at age 5 years. J
Allergy Clin Immunol. 2007; 119:1438-44.
63. Damjanov V, Niki D, Vajagi L, oki D. Uloga zavoda za zatitu zdravlja u unapreenju i zatiti ivotne sredine. Glasnik Zavoda za zatitu zdravlja Srbije. 1997; 71:112-6.

157
65. World Health Organization. Air quality guidelines, global update 2005. Particulate matter, ozone, nitrogen dioxide and sulphur dioxide. Copenhagen: WHO Regional for Europe; 2005.
66. Brauer M, Hoek G, Smit HA, de Jongste JC, Gerritsen J, Potsma DS, et al. Air pollution and development of asthma, allergy and infections in a birth cohort. Eur Respir J. 2007; 29:879-88.
67. McDonnell WF, Abbey DF, Nishino N, Lebowitz MD. Long-term ambient ozone concentration and the incidence of asthma in nonsmoking adults: the AHSMOG study. Environ Res. 2002;
80(2 Pt 1):110-21.
68. Vork KL, Broadwin RL, Blaisdell RJ. Developing asthma in childhood from exposure to secondhand tobacco smoke: insights from a meta-regression. Environ Health Perspect. 2007;
115:1394-400.
69. Douwes J, Pearce N. Invited commentary: is indoor mold exposure a risk factor for asthma? Am
J Epidemiol. 2003; 158:203-6.
70. Johnston SL. Innate immunity in the pathogenesis of virus-induced asthma exacerbations. Proc
Am Thorac Soc. 2007; 4:267-70.
71. Shaheen SO, Newson RB, Henderson AJ, Headley JE, Stratton FD, Jones RW, et al; ALSPAC Study
Team. Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in
childhood. Clin Exp Allergy. 2005; 35:18-25.
72. Shaheen SO, Newson RB, Sherriff A, Henderson AJ, Heron JE, Burney PG, et al; ALSPAC Study
Team. Paracetamol use in pregnancy and wheezing in early childhood. Thorax. 2002; 57:958-63.
73. Pearce N, Douwes J, Beasley R. Is allergen exposure the major primary cause of asthma? Thorax
2000; 55:424-31.
74. Corver K, Kerkhof M, Brussee JE, Brunekreef B, van Strien RT, Vos AP, et al. House dust mite
allergen reduction and allergy at 4 yr: follow up of the PIAMA-study. Pediatr Allergy Immunol.
2006; 17:329-36.
75. Tepas EC, Litonjua AA, Celedn JC, Sredl D, Gold DR. Sensitization to aeroallergens and airway
hiperresponsiveness at 7 years of age. Chest. 2006; 129:1500-8.
76. Bolte G, Bischof W, Borte M, Lehmann I, Wichmann HE, Heinrich J; LISA Study Group. Early endotoxin exposure and atopy development in infants: results of a birth cohort study. Clin Exp
Allergy. 2003; 33:770-6.
158
. .
,

. , . -,
. , .
. 450 . 15-45 . 13%. 2030.

(DALY). , . 2000-3000 DALY
. .

.
. , () . , . .

, , .
60 () , , , .
. , , ,
,
[1, 2].

, [3]. ,
159
, ,
.
, , , .

[4].

(-10: 0099) , . ,
. ,
, , , , [2, 5, 6].
, [7]. 2006.
, , , , , [8].
,
(International Classification of Mental Disorders). , , .
, , ,
[1].
160
. .

450 [7]. , , , ,
, [9].
.
, .
, , , ,
. , 1,5:1 2:1, [10, 11]. , , ,
() [12, 13].

, ;
[14]. 1998. . , , .
28 .
, . 200.000 ,
2004. 14 :
, , . [15]. 4,3% 26,4%
. . 2,4-18,2%, 0,8-9,6% [11, 16].
, , 33,1%
80,9% . 30 .
.
. [17].
,
, [18].
188
161
19652002. . 0,46% ( 0,191%) , 0,33% (0,13-0,88%) 0,4%

(0,16-1,2%) .
, 0,72%
(0,31-2,7%) [19].
, , 1% . 3,06%; 0,87%, 0,32%,
0,18%, 0,35%, 0,42%, 0,21% [20].
. , , , , , , . , , ,
, [21, 22].
[5]
2000. 1,6% , 0,2%, 1,4% , 2006. : 1%,
0,5%, 1,3% ( 1).
2000.
4,9% , 6,2%, 2,1%,
2006. 3,2%
2,9%, 2,6% ( 2).
2006. (2,7%) 2000. (4,8%),
(8,3% 2006, 12,8% 2000. ) [23].

.
, , , , 90% [24,
25, 26].
, 2000. (-10: X60X84).
162
. .
1,6
1,6
1,4
1,4
1,3
1,2
1,0
1,0
% 0,8
0,6
0,5
0,4
0,2
0,2

0
1. 2000.
2006.
7
6,2
6
5
4,9
4
%
3,2
3
2,9
2,6
2,1
2
1

0
2.
2000. 2006.
163
16 1.000 . 40 . , [27].
[28].
15-45 [29]. 45 60%. 2002. 14. , 2030. 12. [9].
, , [30]. . 55. .
,
[31].

,
, ( 3), ,
( 4).
, , ( 4).
2,4/100.000 1998. 3,71/100.000 2008. . 2004. , 2007. ,
. (
3). , 13:1 (1998. ) 3:1 (2008. ) ( 4).
- : 33,68/100.000 75 , 13,98/100.000 70-74 11,94/100.000
50-54 ( 5). 50 .

,
.
.
164
. .

7,1
7,7
7,5
6,8
7
6,1
6,7
6
5
6,1
4,7
4,9
4,6
4,8
4,2
4,3
2,7
2,5
3,7
3,7
3,5
3
2
6,8
3,2
2,7
2,1
1
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
3. (00-99)
19982008.
10

8,9
8,0
8,2
6,7
6,4
6,2
5,8
6
5
4,7
4,6
4,6
4,3
4,1
4,3
4
3
1,9
2
1
0,4
0,8
0,8
1,1
0,8
0,0
0,4
0,0
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
4.
19982008.
165
10,3% 2008. 1998. . 2005, ( 4).

13 , 20012006.
( 6).
1998. 2004. ,
( 6). , 14 ( 7).

[32, 33]. 2001. 90% , 2004.
2008. 56,25%.
( 8).
(10)
2004. , , 2008.
. 23-25% , 2004. 60% ( 9).
40
33,7
35
30
25
20
15
14,0
11,9
8,3
10
6,7
7,0
5
0
0,0
0,0
04
59
0,0
0,0
0,0
0,0
0,0
0,0
0,0
0,0
1014 1519 2024 2529 3034 3539 4044 4549 5054 5559 6064 6569 7074
75
-5
-10
5. -
2008.
166
. .
4,5

4,2
4,3
4,0
3,5
3,3
3,0
3,0
2,5
3,9
3,6
3,5
3,1
2,9
2,5
2,5
2,3
3,2
3,2
3,1
2,9
2,6
2,4
2,4
2,4
2,1
2,0
1,7
1,5
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
6.
(10) 19982008.
9,5
10

9
8
7
5,7
6
5
5,2
4,7
5,1
5,5
5,0
4,2
3,9
3,6
3,5
3
1,4
2
1
0,4
0,8
0,8
0,0
0,0
0,0
0,0
0,0
0,0
2001.
2002.
2003.
2004.
2005.
2006.
0,4
0
1998.
1999.
2000.
2007.
2008.
7.
19982008.
167
120

100
90,0
90,9
90,0
90,0
81,2
80
85,7
75,0
74,0
67,1
64,1
66,7
61,9
% 60
54,5
56,4
56,3
46,6
41,2
40
40,3
30,8
36,4
32,1
35,5
20
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
8.

19982008.
0,40
0,37
0,33
0,31
0,29
0,30
0,30
0,24
0,25
0,25
0,23
0,24
0,25
0,20
0,22
0,29
0,27
0,27
0,25
0,23
0,22
0,22
0,20
0,15
0,16
0,10

0,00
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
9.
19982008.
168
. .
. , . . , 40 . 20 [34].
2008. 45 ,
. ,
11,2% ( 10). ,
. 1999. 13,98/100.000, 2,33/100.000 ( 10).
23,6% 2001,
38,7% 2005. , - , . ( 58,2%) 2005. , (10,68%). ,
2000. , 6:1, , ( 11).
20
18,3
18
17,2
17,8
16,6
16,5
15,7
16
14
16,3
15,1
16,1
15,1
16,0
14,5
14.5
13,1
12,9
12
11,7
10
8
6
1999.
13,0
11,1
10,6
1998.
13,1
2000.
2001.
7,1
7,3
2002.
2003.

2004.
2005.
2006.
2007.
2008.
10. (X60X84)
19982008.
169
2000. , , 18 , , [35]. 31,9%

, 10,4% ( 11).
15,1 100.000 [25]. , 15,1/100.000 ( 12).
- 2008. 75 (43,31/100.000);
70-74 (39,45/100.000) 65-69 (27,81/100.000).
20-24 (5,09/100.000),
15 ( 13). -
75 , .
(. ), , ,
[22, 23].
15-24 , 15-34 .
. 15-24
25
22,6
22,6
21,7
20,1
21,9
19,7
20
17,2
21,4
16,8
15
11,4
11,0
10
10,7
8,0
6,8
5,8
5,3
3,8
7,4
1998.
1999.
2000.
2001.
3,4
3,7
2002.
2003.
3,2
2004.
5,0

2005.
2006.
2007.
2008.
11. 19982008.

170
. .
30
27,62
28,41
25,31
25
20
15
13,88
15,09
14,01
10
6,03
5
2,2
2,6
0

2004-2007.
12.
2007.
50
43,3
45
40
35,0
35
30
27,8
25
22,2
15,0
15
9,6
10
5,8
5
0
20,1
19,3
20
0,0
04
0,0
59
16,6
11,9 12,4
5,1
0,0
1014 1519 2024 2529 3034 3539 4044 4549 5054 5559 6064 6569 7074
75
13. -
2008.
171
16
14,0
14
12
9,9
9,5
10
10,1
7,9
8
6
5,4
4,8
4,7
2,6
2,4
2,3
2
0
1998.
1999.
2000.
2001.
2002.
2003.
2004.
2005.
2006.
2007.
2008.
14. 15-24
19982008.
1.8
1.6
%
1,5
1,5
1,5
1,5
1,4
1,3
1.4
1.2
1,3
1,4
1,4
1,3
1,3
1,3
1,2
1,2
1,0
1,3
1,1
1,0
1,1
1,0
0,9
0.8
0.6
0,6
0,7
2002.
2003.

0.4
1998.
1999.
2000.
2001.
2004.
2005.
2006.
2007.
2008.
15. 1998
2008.
172
. .
(, ), , [21].

15-24 . , 1997. 2007.
. 1997. 17%, 2007. 13%, 43%.

1,05%
1998. 1,11% 2008. ( 14). :
1,47% 1998. 1,26% 2008. ( 15).
19982008. ( ) [5]. 1-4.
,
-
, , ,
,
( 5).
, , , .
1. 19982008.
r
-0,730
0,636
0,639
-0,876
-0,887
-0,770
p
0,011
0,035
0,035
0,000
0,000
0,006
r ( , ); p
2. 19982008.
r
-0,944
0,639
0,937
0,881
p
0,000
0,034
0,000
0,000
173
. ,
. , , , ,
.
3. , -
19982008.

2

1.000

1.000
1.000

r
0,882
0,735
0,606
-0,955
-0,700
-0,718
-0,786
-0,916
0,665
-0,912
-0,891
p
0,000
0,010
0,048
0,000
0,016
0,013
0,021
0,000
0,026
0,000
0,000
4. , 19982008.

1.000
1.000
r
-0,774
0,753
0,764
0,742
0,838
0,858
0,816
0,657
p
0,005
0,007
0,006
0,035
0,002
0,001
0,004
0,039
5. 19982008.

1.000
B
-3,771-02
2,387
SE
0,012
0,184
-0,747
0,589
t
-3,180
12,952
p
0,013
0,006
4,049-02
0,004
0,326
9,850
0,010
-4,525
23,628
0,424
1,807
-0,388
0,979
-10,677
13,077
0,009
0,049
B ; SE ; ;

174
. .

.
, . , 25% [34].
,
. ,
: , , ,
, , . , ,
. ,
. ,
, [36].
DALY 2006.
2030. [9], (DALY/1000) 2002. ( 6). ,
6.
(DALY) 2002. 2030.

/

2002.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
17
2030.
5
8
1
1
12
3
6
4
15
25
7
20
9
10
13
14
-4
-6
+2
+2
-7
+3
+1
+4
-6
-15
+4
-8
+4
+4
+2
+3
: Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. [9]
175
7. (DALY) 2030.

1
2
3
1
2
3
1
2
3
1
2
3.

/

/

/

DALY (%)
12,1
5,7
4,7
9,8
5,9
5,8
9,8
6,7
6,0
14,6
5,8
4,7
: Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. [9]
2030. , ,
( 7).

. ,
.
. , , .
, ,
[7, 37].
, .
. : , , , , , ,
[38]. 15% ,
[39].
, ,
. , .
176
. .
.
, 15%, 2-3% [40].
, , [41, 42].
20 . :
,
( ), ,
[43, 44]. [45].
, 30%
( 50% ) [46]. 5%
,
[47].

[48].
, . 40% - [49].
,
.
(. ). , .
. . , ,
, [50].
, , ,
.
67% ,
45,4% . 2004. , 12 76,3-85,4%
, 35,5-50,3% .
,
, : , , , , ,
177
.
[51].

, , 2000. 30,8% ,
12%. , [32].
.
[50]. , , . .
[52].
,
. ,
. , , .
, .
. . , , , , . , , , .
,
. . [53].
;
, .
,
178
. .
. , , .
2009. [5]
2006. 38,9% , , . , 7,1% ,
( 16).
0 8 (26,9%
28,8% ) 5 2000. , 9 2006. (18% 17% ). 2006. 0 10
9.
. , , ( 8).
(55,1%)
2000. , , , .
2006. 38%. 2000. 37,5% , 2006.
45
42,0
40
34,2
35
30
25,0
%
26,0
26,3
25
22,0
20
15
10
7,9
6,0
5
0
5,3
4,0
1,3
16. , 2006.
179
30%. 2000. 2006. (9,1% 1,2%); (6,2% 0,7%), (19,8% 1,2%),

(3,3% 1%), (6,8% 0,7%), (17,1% 1,9%)
(11% 1,5%) ( 9).
2000. 60,2%
, 61,7%
58,6% . 2006.
(41,6%), (44,1%) (39%) ( 10).
43,9%
, 2000. , 58,6% . .
,
8. 2006.
(%)

1
2
3
4
5
6
7
8
9
10,1
20,0
31,0
16,0
10,1
6,4
2,7
3,4
0,2
100
10,5
12,7
17,4
11,3
15,2
11,5
12,7
5
2,9
100
60
13,2
8,1
5,4
0,5
2,2
2,7
5,4
2,5
100
4,2
5,2
4,4
18,0
10,8
19,5
26,4
8,1
3,4
100
3,7
3,4
0,7
2,0
8,1
4,4
5,9
16,0
55,7
100
1,2
2,7
1,2
9,6
7,1
19,2
23,2
26,1
9,6
100
5,6
31,6
18,1
14,2
6,6
6,9
10,8
2,7
3,4
100
3,7
10,0
17,9
15,4
16,4
17,9
5,1
9,8
3,7
100
1,0
1,2
1,2
8,3
25,2
11,8
10,3
22,5
18,4
100
9.
2006.

180
1,2
9,5
25,1
34,5
20,4
7,3
1,9
100
(%)

0,7
1,2
1,0
0,7
3,4
10,9
1,9
4,4
14,1
29,4
7,1
14,4
28,7
39,7
24,6
33,3
33,1
15,1
32,6
34,3
18,0
1,7
30,9
10,9
1,9
1,9
1,9
1,9
100
100
100
100
1,9
15,3
28,7
31,45
19,0
1,7
1,9
100
1,5
4,6
16,8
41,4
30,9
3,2
1,7
100
. .
2000. , 40% . . 11,7% , 2000.

(16,5%). , , , ,
, , , , , , , 4,4%
10. 2000. 2006.
(%)
2000.
5,1
3,8
0
5,9
5,1
5,0
3,4
58,6
4,2
1,3
0
0
0
5,1
0
0
100
2006.
3,3
1,4
0,5
5,2
0,9
1,9
0,9
44,1
5,7
0,5
1,4
0
3,3
26,5
1,9
2,4
100
(%)
2000.
2006.
2,9
1,0
2,9
2,0
2,5
1,0
6,7
7,0
0,8
1,5
5,0
5,0
2,5
1,5
61,7
39,0
3,3
7,0
0,4
1,5
0,0
0
0
3,0
0
4,5
7,5
23,5
0
5,0
0
2,0
100
100
11.
4,6
1,2
0
0
2,5
2,9
0
6,6
3,7
3,3
2,5
1,2
2,1
0,4
32,8
34,7
60,6
58,3
11,6
17,7
73,9
70,0
10,8
14,5
54,4
59,7
8,3
5,0
82,2
76,4
17,4
13,2
53,1
68,2
36,0
34,7
59,0
63,2
22,4
24,5
76,3
75,1
2,1
13,3
34,9
9,5
27,0
1,2
1,2
0,4
8,6
22,7
16,1
17,4
0
0
181
. 2006. (62,8%), (32,6%)

(21,7%). , , , , .
, ( 10 11).

, .
,
.
,
. , , ,
.
. , , , [54]. .
, , ,
.
, , ,
. .
, ,
, , .
, , ,
.
,
. , , ,
( , , ),
. , , .
.
182
. .
, ,

, ,
. , .
, , ,
, . ,
[55].

. 15 3% . , , , [56].
60-80% . . 2000. 32 .
, [7].
12 , , , .
2.000 3.000 DALY
,
(3-4 , 7-9 ).
. 350-700 ,
[12].
,
:
, ;
,

[57];
, , , , .
183

, ,

, [8].
12.

:
(DALY

:

:

)
:

:

:
(

:

)
:

:

(DALY :

:
)

:

254
373
364
353
300
392
312
365
322
413
346
422
1174
1953
1806
1789
1937
1747
245
307
287
307
284
330
1985
2998
2779
2862
2867
2891
0,47
1,81
1,61
1,32
0,52
0,75
0,48
1,80
1,61
1,32
0,52
0,75
1,80
4,80
3,99
3,56
2,81
2,59
0,15
0,27
0,21
0,23
0,16
0,20
2,9
8,7
6,5
4,1
4,5
544
206
226
267
574
647
203
262
298
560
652
407
452
502
690
1588
1155
1339
1350
1765
: World Health Organization. Disease Control Priorities Related to Mental, Neurological, Developmental and Substance Abuse Disorders.
2nd ed. Geneva: WHO; 2006. [12]
184
. .

:
) ;
) .
, , . , ,
, .

,
, . , . , ( ).
,
, ,
.
[56].

.
.
19. [58].

. , , . .
.
,

[59].
185
,
(amafufunyana) (ukuthwasa), . , . ,
, . , . ,
. .
, , . [60].
15. , , (Bethlem Royal Hospital). 18. 19. , , ,
.
. , , . 155.000 , 559.000
[61]. .
: ,
, , [62].
. 1978.
, , ,
15 . [63].
() , , , , . , [63].
. 2005. [64], ( 13).

.
,
186
. .
13.
100.000
0,04
2
0,95
9,8
0,2
0,32
1,2

0,2
2,6
1,25
24,8
0,1
0,5
2
0,05
2,8
0,6
3,1
0,03
0,03
0,6
: World Health Organization. Mental Health Atlas 2005. Geneva: WHO; 2005. [51]
14.
10.000

0,34
2,6
1,07
8
0,33
1,06
1,69

73
80,6
83
63,5
82,7
60,1
68,6

( 14). , , ,
.

,
.

. ,
,
187
. ,
. . : ,
. , , ( ), [65].

. , , .
. ,
, .

, , . , ,
. , . ,
.

,
. , , . , .
,
. .
, . , ,
, , ,
188
. .
. .

. , .
. [65].
, . ,
, .
, . ,
. ( ). , , ,
.

,
, .
,
. ,
.

.
, (
). . , .
, , ,
189
. ,
, , , .

,
, , , . , .
, .
, .
,
. . , , , . , , , , , .
,
[66, 67].

, , [7]. , . , , , , , ,
.
[12]. .
190
. .
,
,
.
, , .
. , , , .
. .

, .
, , , , , . , ,

, .

, . , , , ,
. ,
,
.
11 20% 30%,
[52]. , ,
191
.
. , ,
, , ,
. , .
, .
( ) , , .
15.
15
; 62%
10
15 ; 50%

8-12

67.7%
72.2%
42%
38.5%
51.8%
20.4%
55%
15%
41%
48%
87%
60%
76.7%
9.4%
80.2%
24.8%
41%
27%
26%
25%
39.9%
60%
52%

: Murthy RS, Lakshimanarayana R. Mental health consequences of war: a brief review of research findings. World Psychiatry. 2006;
5:25-30. [71]
192
. .
, , . , , , , ,
. ; , , . : ,
, , , , , , [68, 69].
[70].
, , , [71].
( 15). ,
, , -
.
-

. , ,
. , , . . .
, . , , , [72].
.
193
. ( ), , . , ( )
, , .

, .
, . , ,
, ,
. .
, [73].

. .

:
) ( );
) (
);
) (
,
).

.
, .
, ,
,
. , . :
,
, , , -
, .
194
. .
.
. ,
. .
. , .
.
:
1. , . . ,
, ,
2030. DALY . ,
;
2. ,
. , . , ;
3. . ,
, ;
4.
,
, , , .
5.

. ,
, () .
195
. 1998-2008., . . .
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
196
Freeman M, Funk M. Public mental health. In: Detels R, Beaglehole R, Lansang MA, Gulliford
M, editors. Oxford Textbook of Public Health. 5th ed. New York: Oxford University Press; 2009.
p.1081-100.
oki D, Jakovljevi , Jakovljevi . Socijalna medicina. Kragujevac: Medicinski fakultet
Milovanovic S, Jasovic-Gasic M, Pantovic M, Djukic-Dejanovic S, Jovanovic AA, Damjanovic
A, et al. The historical development of psychiatry in Serbia. Psychiatria Danubina. 2009;
21(2):156-65.
Saraceno B, van Ommeren M, Batniji R, Cohen A, Gureje O, Mahoney J, et al. Barriers to improvement of mental health services in low-income and middle-income countries. Lancet. 2007;
370:1164-74.
Vui-Jankovi M, Kisin , Nikoli D. Uloga osnovne zdravstvene zatite u otkrivanju, leenju
i suzbijanju bolesti zavisnosti. Prvi simpozijum domova zdravlja SRJ sa meunarodnim ueem. Zbornik radova. Novi Sad, 1995.
World Health Organization. The World Health Report 2001 Mental Health: New Understanding,
New Hope. Geneva: WHO; 2001.
World Health Organization. Economic Aspects of the Mental Health System: Key Messages to
Health Planners and Policy Makers. Geneva: WHO; 2006.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030.
PLoS Med. 2006; 3(11):e442.
Ignjatovi-Risti D, uki-Dejanovi S, Ravani D, Janji V, Borovanin M, Radmanovi B, et al.
Mogui prilazi anoreksiji nervozi patnja za pojedinca, porodicu, drutvo. Medicinski asopis. 2010; 44(1):37-40.
Mihajlovic G, Hinic D, Damjanovic A, Gajic T, Djukic-Dejanovic S. Excessive internet use and depressive disorders. Psychiatria Danubina. 2008; 20(1):5-14.
World Health Organization. Disease Control Priorities Related to Mental, Neurological,
Developmental and Substance Abuse Disorders. 2nd ed. Geneva: WHO; 2006.
Radovanovi S, Mili , Koci S, Milovanovi N. Uestalost korienja psihoaktivnih supstanci
kod srednjokolske omladine Kragujevca. Medicinski asopis. 2008; 42(1):30-3.
Popovi P, Koci S, Mili , oki D. Karakteristike mentalnog zdravlja odraslih. Medicus. 2003;
4(2):46-51.
World Health Organization. World Health Report 2004 Changing History. Geneva: WHO; 2004.
Borovanin M, uki-Dejanovi S, Mihajlovi G. Bioloke osnove anksioznosti i novine u psihofarmakolokom tretmanu anksioznih poremeaja. Engrami. 2008; 30(3-4):53-9.
Kessler RC, Haro JM, Heeringa SG, Pennell BE, Ustn TB. The World Health Organization World
Mental Health Survey Initiative. Epidemiol Psichiatr Soc. 2006; 15:161-6.
uki-Dejanovi S, Borovanin M. Neuroplastinost i nove terapijske mogunosti u shizofreniji. Engrami. 2010; 32(4):45-52.
. .
19. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia.
PloS Med. 2005; 2(5):e141.
20. Perl J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isomets E, Pirkola S, et al. Lifetime prevalence of
psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007; 64:19-28.
21. World Health Organization. The World Report on Violence and Health. Self-directed vilence.
Geneva: WHO; 2002.
22. Kozari-Kovai D. Epidemiologija suicida u Hrvatskoj neki svetski epidemioloki pokazatelji suicida. Zbornik saetaka. Prvi Hrvatski kongres o suicidalnom ponaanju, Zagreb, decembar 2000.
23. Institut za javno zdravlje Srbije Dr Milan Jovanovi Batut. Zdravlje stanovnika Srbije
Batut; 2008.
24. Bertolote JM, Fleischman A, De Leo D, Wasserman D. Psychiatric diagnoses and suicide: revisiting the evidence. Crisis. 2004; 25:147-55.
25. Horwath E, Cohen RS, Weissman MM. Epidemiology of depressive and anxiety disorders. In:
Tsuang MT, Tohen M, editors. Textbook in Psychiatric Epidemiology. 2nd ed. New York: WileyLiss; 2002. p.389-426.
26. Ustn TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004; 184:386-92.
27. Plai A, Grbi G, Koci S, Radovanovi S. Socijalnomedicinske karakteristike suicida na teritoriji grada Kragujevac u periodu 19962001. Materia Medica. 2008; 24:(2):12-9.
28. Aaron R, Joseph A, Abraham S, Muliyil J, George K, Prasad J, et al. Suicides in young people in
rural southern India. Lancet. 2004; 363:1117-8.
29. Koci S, Mili , Grbi G, Plai A, Tati Z. Godine starosti kao faktor rizika od suicida. Vojnosanit
Pregl. 2008; 65(5):371-5.
30. Heil H, Haukka J, Suvisaari J, Lnnqvist J. Mortality among patients with schizophrenia and
reduced psychiatric hospital care. Psychol Med. 2005; 35:725-32.
31. Dewey ME, Saz P. Dementia, cognitive impairment and mortality in persons aged 65 and over
living in the community: a systematic review of the literature. Int J Geriatr Psychiatry. 2001;
16:751-61.
32. World Health Organization. Global Status Report on Alcohol. Geneva: WHO; 2004.
33. Miovi P, oki D, i sar. Zdravstveno stanje stanovnitva Srbije od 1986. do 1996. analitika
34. Tyrer P, Tyrer F. Public mental health. In: Detels R, McEwen J, Beaglehole R, Tanaka H, editors.
Oxford Textbook of Public Health. 4th ed. New York: Oxford University Press; 2002. p.1309-28.
2003.
36. Vucic-Jankovic M, Kisin D, Trajkovic-Pavlovic Lj, Marjanovic M. The impact of the economy crisis on public health in the FR Yugoslavia. Fifth International Conference on Travel Medicine.
Abstract Book. Geneva, 1997.
37. Grbi G, oki D, Koci S, Mitrainovi D, Raki Lj, Prelevi R, et al. Uticaj demografskih i socijalno-ekonomskih odlika na kvalitet ivota ljudi. Srp Arh Celok Lek. 2011; 139(5-6):360-5.
38. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without mental health. Lancet. 2007; 370:859-77.
39. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent
of psychiatric and medical comorbidity. Arch Gen Psychiatry. 2005; 62:903-10.
40. Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol. 2005; 19(6 Suppl):56-65.
197
41. Vucic-Jankovic M, Ilic V, Radulovic T,Velickovic M. Sexual behavior and sexually transmitted
diseases among injecting drug users in Yugoslavia. 7th International Congress for Infectious
Diseases. Abstract Book. Hong Kong, 1996.
42. Vucic-Jankovic M, Ilic V, Radulovic T,Velickovic M. HIV prevalence and behavior factors related
to injecting drug users. XI International Conference on AIDS. Abstract Book.Vancouver, 1996.
43. oki D, Deletovi A, Popovi R, iri , Tomi V. Uloga instituta i zavoda za zatitu zdravlja u
prevenciji HIV bolesti. Glasnik Zavoda za zatitu zdravlja Srbije. 1999; 73:1-9.
44. Popovi R, Deletovi A, oki D, Matovi-Miljanovi S. Razvoj programa HIV AIDS prevencije. Glasnik Zavoda za zatitu zdravlja Srbije. 1999; 73:10-5.
45. Njenga FG, Nguithi AN, KangEthe RN. War and mental disorders in Africa. World Psychiatry.
2006; 5:38-9.
46. Grant I, Marcotte TD, Heaton RK; HNRC Group. Neurocognitive complications of HIV disease.
Psychol Sci. 1999; 10:191-5.
47. Catalan J, Meadows J, Douzenis A. The changing pattern of mental health problems in HIV infection: the view from London, UK. AIDS Care. 2000; 12:333-43.
48. Tomi V, oki D. Znaaj socijalno-psiholokih aspekata AIDS-a u planiranju strategije prevencije i unapreenja zdravlja. Glasnik Zavoda za zatitu zdravlja Srbije. 1999; 73:29-35.
49. Collins PY, Holman AR, Freeman MC, Patel V. What is the relevance of mental health to HIV/
AIDS care and treatment programs in developing countries? A systematic review. AIDS. 2006;
20:1571-82.
50. World Health Organization. Dollars, DALYs and Decisions: Economic Aspects of the Mental
Health System. Geneva: WHO; 2006.
51. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World
Health Organ. 2004; 82:858-66.
52. Patel V, Kleinman A. Poverty and common mental disorders in developing countries. Bull World
Health Organ. 2003; 81:609-15.
53. Taylor L, Taske N, Swann C, Waller S. Public Health Interventions to Promote Positive Mental
Health and Prevent Mental Health Disorders Among Adults. London: National Institute for
Health and Clinical Excellence; 2007.
54. Koci S, oki D, Radovanovi S, Popovi P, Radevi S. Povrede u drumskom saobraaju na teritoriji grada Kragujevca. Zdravstvena zatita. 2010; 39(6):25-8.
55. Petersen I, Swartz L. Primary health care in the era of HIV/AIDS. Some implications for health
system reform. Soc Sci Med. 2002; 55:1005-13.
56. McDaid D. Key Issues in Mental Health Policy and Practice Development across Europe.
European Observatory on Health Systems and Policies Policy Brief. Copenhagen: World Health
Organization; 2005.
57. Mihajlovic G, Djukic Dejanovic S, Jovanovic-Mihajlovic N, Janjic V, Jovanovic M, Petrovic D, et al.
Comparison of safety between individualized and empiric dose regimen of amitriptyline in the
treatment of major depressive episode. Psychiatria Danubina. 2010; 22(2):354-7.
58. Tyrer P, Steinberg D. Models for Mental Disorders: Conceptual Models in Psychiatry. 3rd ed.
Chichester: John Wiley & Sons; 1998.
59. Chang D, Yifeng X, Kleinman A, Kleinman J. Rehabilitation of schizophrenia patients in China:
the Shanghai model. In: Cohen A, Kleinman A, Saraceno B. World Mental Health Casebook. New
York: Kluwer Academic; 2002. p.27-50.
60. Niehaus DJ, Oosthuizen P, Lochner C, Emsley RA, Jordaan E, Mbanga NI, et al. A culture-bound
syndrome amafufunyana and a culture-specific event ukuthwasa: differentiated by a family
history of schizophrenia and other psychiatric disorders. Psychopathology. 2004; 37:59-63.
61. Hfner H, van der Heiden W. The evaluation of mental health care systems. Br J Psychiatry.
1989; 155:12-7.
62. Drew N, Funk M. Commentary on The Israeli model of the district psychiatrist a fifty-year
perspective. Isr J Psychiatry Relat Sci. 2006; 43(3):189-94.
198
. .
63. Funk M, Drew N, Saraceno B, Caldas De Almeida JM, Agossou T, Wang X, et al. A framework for
mental health policy, legislation and service development: addressing needs and impoving services. Harvard Health Policy Review. 2005; 6:57-69.
64. World Health Organization. Mental Health Atlas 2005. Geneva: WHO; 2005.
65. Funk M, Saraceno B, Drew N, Lund C, Grigg M. Mental health policy and plans: promoting an
optimal mix of services in developing countries. Int J Mental Health. 2004; 33:4-16.
66. Grozdanov J, Gruji V, oki D, Jelaa P. Razvoj zdravstvenog sistema, mesto i uloga zavoda za
zatitu zdravlja. Glasnik Zavoda za zatitu zdravlja Srbije. 1997; 71:35-40.
68. Baingana F, Bannon I, Thomas R. Mental Health and Conflicts: Conceptual Framework and
Approaches. Washington: World Bank; 2005.
69. Djukic-Dejanovic SM, Janji V, Milovanovi D. Etiopatogeneza nesanice. Psihijatrija danas. 2003;
35(1):5-21.
70. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and
Afganistan: mental health problems, and barriers to care. N Engl J Med. 2004; 351:13-22.
71. Murthy RS, Lakshimanarayana R. Mental health consequences of war: a brief review of research findings. World Psychiatry. 2006; 5:25-30.
72. Cohen A. Our Lives Were Covered in Darkness. The Work of the National Literacy Mission
in Northern India. In: Cohen A, Kleinman A, Saraceno B. World Mental Health Casebook. New
York: Kluwer Academic; 2002. p. 153-189.
73. Visser M. Contextualising Community Psychology in South Africa. Pretoria: Van Schaik
Publishers; 2007.
199

Đokić D I Saradnici. Epidemiološke Odlike, Faktori Rizika I Socijalnomedicinski Značaj Hroničnih Nezaraznih Oboljenja. Monografija. Kragujevac Institut Za Javno Zdravlje, 2011. 81-113

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Đokić D I Saradnici. Epidemiološke Odlike, Faktori Rizika I Socijalnomedicinski Značaj Hroničnih Nezaraznih Oboljenja. Monografija. Kragujevac Institut Za Javno Zdravlje, 2011. 81-113

Uploaded by

Copyright:

Available Formats

,

(. waisthip ratio WHR). WHR 0,95 0,85 .

, . , , 4,85 , 2,53 1,24

(Helicobacter pylori) 20-30%

100.000 . , 1,5:1, , . , [43].

3-5 . . - BRCA1 17q BRCA2 13q, .

orevi M, Mitrovi S, orevi G, Jovanovi B. Endometrioidni tumor ovarijuma i uterusa,

. 1869. , , 1956. [1, 2].

(-10: 10-14, -24)

<6,1 mmol/l (<110 mg/dl)

6,1-7,0 mmol/l (110-126 mg/dl)

7,0 mmol/l (126 mg/dl)

<7,8 mmol/l (<140 mg/dl)

1; [41]. , , , . [41, 42].

. 18% 2 , 11% , [64, 65].

59 14 1519 24 2529 34 3539 44 4549 54 5559 64 6569 74 75

sthma, . , . , 17. [13].

12. (43) 1998

ECRHS 3.000 20. 44.

16. (45) 19982008.

. , 20% 40% [36].

. 450 . 15-45 . 13%. 2030.

19652002. . 0,46% ( 0,191%) , 0,33% (0,13-0,88%) 0,4%

10,3% 2008. 1998. . 2005, ( 4).

2000. , , 18 , , [35]. 31,9%

30%. 2000. 2006. (9,1% 1,2%); (6,2% 0,7%), (19,8% 1,2%),

2000. , 40% . . 11,7% , 2000.

. 2006. (62,8%), (32,6%)

You might also like